



# **STIC Search Report**

## **Biotech-Chem Library**

STIC Database Tracking Number: 97964

TO: Michael Borin  
Location: 12a 01 / 12d01  
Wednesday, July 16, 2003  
Art Unit: 1631  
Phone: 308-4506  
Serial Number: 09 / 586529

From: Jan Delaval  
Location: Biotech-Chem Library  
CM1-1E07  
Phone: 308-4498

[jan.delaval@uspto.gov](mailto:jan.delaval@uspto.gov)

### Search Notes

Jan Delaval  
Reference Librarian  
Biotechnology & Chemical Library  
CM1 1E07 - 703-308-4498  
[jan.delaval@uspto.gov](mailto:jan.delaval@uspto.gov)

10 Jan Delaval 97964  
RECEIVED

Access DB# \_\_\_\_\_

## SEARCH REQUEST FORM

Scientific and Technical Information Center

(S/TC)

Requester's Full Name: M. Borin Examiner #: 74104 Date: 07/02  
Art Unit: 1631 Phone Number 305-4506 Serial Number: 09/586529  
Mail Box and Bldg/Room Location: \_\_\_\_\_ Results Format Preferred (circle): PAPER DISK E-MAIL

**If more than one search is submitted, please prioritize searches in order of need.**

\*\*\*\*\*

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: \_\_\_\_\_

Inventors (please provide full names): \_\_\_\_\_

Earliest Priority Filing Date: \_\_\_\_\_

*\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

*Please search claims 1, 2, 10, 24, 25*

*Thank you :-)*

*M. Borin*

Jan Delaval  
Reference Librarian  
Biotechnology & Chemical Library  
CMI 1E07 - 703-308-4498  
jan.delaval@usplo.gov

\*\*\*\*\*  
**STAFF USE ONLY**

	Type of Search	Vendors and cost where applicable
Searcher: <u>Jan</u>	NA Sequence (#) _____	STN <input checked="" type="checkbox"/> _____
Searcher Phone #: <u>4498</u>	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>7/15/02</u>	Bibliographic <input checked="" type="checkbox"/> _____	Dr.Link _____
Date Completed: <u>7/16/02</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Clerical Prep Time: <u>7:23</u>	Patent Family _____	WWW/Internet _____
Online Time: <u>+150</u>	Other _____	Other (specify) _____



# STIC SEARCH RESULTS

## Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact*:

Mary Hale, Information Branch Supervisor  
308-4258, CM1-1E01

## Voluntary Results Feedback Form

➤ I am an examiner in Workgroup:  Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature  
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library CM1 – Circ. Desk



=> fil wpix

FILE 'WPIX' ENTERED AT 14:08:52 ON 16 JUL 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE LAST UPDATED: 10 JUL 2003 <20030710/UP>  
MOST RECENT DERWENT UPDATE: 200344 <200344/DW>  
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> NEW WEEKLY SDI FREQUENCY AVAILABLE --> see NEWS <<<

>>> SLART (Simultaneous Left and Right Truncation) is now  
available in the /ABEX field. An additional search field  
/BIX is also provided which comprises both /BI and /ABEX <<<

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,  
SEE <http://www.derwent.com/dwpi/updates/dwpicov/index.html> <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
GUIDES, PLEASE VISIT:  
[http://www.derwent.com/userguides/dwpi\\_guide.html](http://www.derwent.com/userguides/dwpi_guide.html) <<<

=> d all abeq tech abex tot

L25 ANSWER 1 OF 8 WPIX (C) 2003 THOMSON DERWENT

AN 2002-590755 [63] WPIX

DNC C2002-167209

TI Identifying oligonucleotide sequences for amplifying a unique sequence  
within a genomic region, useful for producing unique, repeat-free probes,  
comprises identifying repeat sequence-free subregions within a genomic  
region.

DC B04 D16

IN ALBERTSON, D G; COLLINS, C; GRAY, J W; PINKEL, D;

VOLIK, S; VOLIK, S V

PA (ALBE-I) ALBERTSON D G; (COLL-I) COLLINS C; (GRAY-I) GRAY J W; (PINK-I)  
PINKEL D; (VOLI-I) VOLIK S; (REGC) UNIV CALIFORNIA

CYC 100

PI WO 2002057481 A2 20020725 (200263)\* EN 30p C12Q000-00 <--

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
NL OA PT SD SE SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR  
KZ LC LK LR LS LT LU LV MA MD MG MK MN M

RO RU SD SE SG SI SK SL TJ TM TN TR TT T W

US 2003022166 A1 20030130 (200311)

ADT WO 2002057481 A2 WO 2002-US365 20020107; US 200:  
20010119

PRAI US 2001-766450 20010119

IC ICM C12Q000-00; C12Q001-68

ICS C07H021-04; G01N033-48; G01N033-50; G06F01

AB WO 200257481 A UPAB: 20021001

NOVELTY - Identifying (M1) oligonucleotide sequences for amplifying a  
repeat sequence-free subsequences within the genomic region of interest to  
a nucleotide sequence database, to identify nucleotide sequences within  
the nucleotide sequence database that are substantially similar to the  
repeat sequence-free subsequences, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) identifying (M2) oligonucleotide sequences for amplifying a

*Because of date  
limitation, I  
could not find  
a really outstanding  
ref for 102*

unique sequence within a genomic region of interest, comprises:

(a) executing a first process on a digital computer to identify repeat sequences that occur within the genomic region of interest;

(b) executing a second process on a digital computer to compare repeat sequence-free subsequences within the genomic region of interest to a nucleotide sequence database, where nucleotide sequences within the nucleotide sequence database that are substantially similar to the repeat sequence-free subsequences are identified;

(c) executing a third process on a digital computer to identify oligonucleotide sequences that are suitable for use as primers in an amplification reaction to amplify a product within any of the repeat sequence-free subsequences for which a defined number of substantially similar sequences are identified in the nucleotide sequence database; and

(d) outputting the oligonucleotide sequences;

(2) identifying (M3) oligonucleotide sequences for amplifying a unique sequence within a genomic region of interest comprising:

(a) analyzing a genomic nucleotide sequence that encompasses the genomic region of interest to identify repeat sequences within the genomic region;

(b) comparing at least one repeat sequence-free subsequence within the genomic nucleotide sequence to a nucleotide sequence database to identify sequences within the database that are substantially similar to the repeat sequence-free subsequence;

(c) for at least one of the repeat sequence-free subsequences for which a defined number of substantially similar sequences are identified within the nucleotide sequence database, selecting oligonucleotide sequences that are suitable for use as primers in an amplification reaction to amplify a product within the repeat sequence-free subsequence;

(3) a computer program product designing and outputting oligonucleotide sequences suitable for use as primers to amplify unique sequences within a genomic region of interest, comprising a storage structure having computer program code embodied within, where the computer program code comprises:

(a) computer program code for analyzing a nucleotide sequence encompassing the genomic region of interest to identify repeat sequences within the nucleotide sequence;

(b) computer program code; which for each subsequence of the nucleotide sequence that does not contain any of the repeat sequences, compare the subsequence against a nucleotide sequence database to identify nucleotide sequences within the database that are substantially similar to the subsequence;

(c) a computer program code which identifies oligonucleotide sequences suitable for use as primers in an amplification reaction to amplify a product within the subsequence, for each of the subsequences for which a defined number of substantially similar sequences are found in the database, and

(d) computer program code for outputting the oligonucleotide sequences; and

(4) identifying (M4) genes within a genomic region of interest comprising:

(a) executing a first process on a digital computer to identify repeat sequences that occur within the genomic region of interest;

(b) executing a second process on a digital computer to compare repeat sequence-free subsequences within the genomic region of interest to a nucleotide sequence database, where nucleotide sequences within the nucleotide sequence database that are substantially similar to the repeat sequence-free subsequences are identified;

(c) executing a third process on a digital computer to select repeat sequence-free subsequences having no substantially similar sequences to identify a repeat sequence-free subsequence may represent a gene family;

(d) identify oligonucleotide sequences that are suitable for use as primers in an amplification reaction to amplify a product within any of the repeat sequence-free subsequences for which a defined number of

substantially similar sequences are identified in the nucleotide sequence database; and

(e) outputting the oligonucleotide sequences.

USE - (M1) is useful for identifying oligonucleotide sequences for amplifying a unique sequence within a genomic region, and for producing unique, repeat-free probes which represent truly unique sequences within the genome. (M1) is also useful for the identification of candidate genes within a genetic interval, and in the identification of potential coding sequences within the region. Those sequences found to lack both known repetitive sequences as well as close homologs in the genome may be used to design primers that would allow amplification of unique products for use as probes or array targets. The probes or array targets can be used without adding an excess of additional unlabeled repeat sequences for enhancing the speed, simplicity, and efficiency of the reaction compared to traditional methods.

ADVANTAGE - (M1) is rapid, efficient, and automated for identifying unique sequences within the genome. (M1) is inherently high-throughput and easy to automate, and is independent of any bias towards previously identified expressed sequences.

Dwg.0/2

FS CPI

FA AB; DCN

MC CPI: B04-B03C; B04-E05; B11-C08E3; B11-C08E5; B11-C08E6;  
B11-C08F1; B12-K04F; D05-H09; D05-H12D;  
D05-H12D1; D05-H18B

TECH UPTX: 20021001

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: The genomic region is from a human genome. The number of substantially similar sequences is zero. The oligonucleotide sequences are outputted by displaying the sequences on a computer screen or on a computer printout, or by executing a fourth process on a digital computer to direct the synthesis of oligonucleotide primers comprising the oligonucleotide sequences. The computer directs the synthesis of the oligonucleotide primers by ordering the synthesis from an external source, and is in communication with an oligonucleotide synthesizer, which directs the synthesis of the oligonucleotide primers. The substantially similar sequences are at least 50-90% identical to the repeat sequence-free subsequences. The first process is executed using Repeat Masker software, a Basic local alignment search tool (BLAST) algorithm or a Primer3 software. (M2) further comprises producing an amplification product using the oligonucleotide primers, where the amplification product is a FISH probe, preferably fluorescently labeled, or is an array CGH target. (M3) further comprises displaying the oligonucleotide sequences on a computer screen or on a computer printout, and directing the synthesis of oligonucleotide primers comprising the oligonucleotide sequences by ordering the synthesis of the primers from an external source.

L25 ANSWER 2 OF 8 WPIX (C) 2003 THOMSON DERWENT

AN 2002-303417 [34] WPIX

CR 1991-165919 [23]; 1992-217417 [27]; 1992-286380 [35]; 1993-303497 [38];  
1995-319885 [41]; 1999-037064 [04]; 1999-105095 [09]; 1999-579905 [49];  
1999-619646 [53]; 2001-564345 [63]; 2002-163200 [21]; 2003-352179 [33];  
2003-352608 [33]

DNC C2002-088220

TI Comparative genomic hybridization to determine relative copy numbers of nucleotide sequences in subject and reference genomes as functions of locations, by comparing signal intensities of subject and reference genes.

DC B04 D16

IN GRAY, J W; KALLIONIEMI, A; KALLIONIEMI, O; PINKEL, D; SAKAMOTO, M; WALDMAN, F

PA (REGC) UNIV CALIFORNIA

CYC 1

PI US 2002028460 A1 20020307 (200234)\* 52p C12Q001-68

ADT US 2002028460 A1 CIP of US 1991-696948 19910508, CIP of US 1992-846659 19920304, Cont of US 1993-132172 19931006, Div ex US 1994-223905 19940406, Cont of US 1995-565304 19951127, Cont of US 1999-311835 19990514, US 2001-912818 20010724

FDT US 2002028460 A1 Cont of US 5976790

PRAI US 1993-132172 19931006; US 1991-696948 19910508; US 1992-846659 19920304; US 1994-223905 19940406; US 1995-565304 19951127; US 1999-311835 19990514; US 2001-912818 20010724

IC ICM C12Q001-68

ICS C12P019-34

AB US2002028460 A UPAB: 20030526

NOVELTY - Comparative genomic hybridization (CGH) (M1) for determining relative copies of nucleic acid sequence in one or more subject genomes or its portions as a function of the location of those sequences in a reference genome involves comparing intensities of the signals from each labeled subject nucleic acid and/or the differences in the ratios between different signals from the labeled sequences.

DETAILED DESCRIPTION - In M1, comparing copy numbers of different DNA or RNA sequences in a subject cell or cell population involves:

(a) extracting the DNA or RNA from the subject cell or from a number of cells of the subject cell population;

(b) amplifying the extracted subject DNA or RNA, if necessary;

(c) labeling the subject DNA or RNA;

(d) hybridizing the labeled subject DNA or RNA in situ to reference metaphase chromosomes after substantially removing from the labeled DNA or RNA those repetitive sequences that could bind to multiple loci in the reference metaphase chromosomes, and/or after blocking the binding sites for those repetitive sequences in the reference metaphase chromosomes by prehybridization with appropriate blocking nucleic acids, and/or blocking those repetitive sequences in the labeled DNA or RNA by prehybridization with appropriate blocking nucleic acid sequences, and/or including such blocking nucleic acid sequences for the repetitive sequences during the hybridization, where the DNA or RNA sequences in the labeled subject DNA or RNA that bind to single copy sequences in the reference metaphase chromosomes are substantially retained, and those single copy DNA or RNA sequences as well as their binding sites in the reference metaphase chromosomes remain substantially unblocked both before and during the hybridization;

(e) rendering the bound, labeled DNA or RNA sequences visualizable, if necessary;

(f) observing and/or measuring the intensity of the signal from the labeled subject DNA or RNA sequences as a function of position on the reference metaphase chromosomes; and

(g) comparing the copy numbers of different DNA or RNA sequences of the subject DNA or RNA by comparing the signal intensities at different positions on the reference metaphase chromosomes, where the greater the signal intensity at a given position, the greater the copy number of the sequences in the subject DNA or RNA that bind at that position.

INDEPENDENT CLAIMS are also included for the following:

(1) quantitatively comparing (M2) copy numbers of different DNA sequences in one subject cell or cell population relative to copy numbers of substantially identical sequences in another subject cell or cell population;

(2) determining (M3) the ratio of copy numbers of different DNA sequences in one subject cell or cell population to copy numbers of substantially identical sequences in another cell or cell population; and

(3) detecting (M4) amplification of a certain sequence or group of sequences in a subject cell or cell population.

USE - M1 is useful for comparing copy numbers of different DNA or RNA sequences in a subject cell or cell population (claimed). M1 is useful for finding regions in normal genomes which when altered in sequence copy number contribute to diseases such as cancer or birth defects, to detect sequence copy number imbalances throughout an entire genome in one

hybridization, to map gains and/or losses of sequences in a genome and/or to provide a copy number karyotype of a subject genome, for prenatal or perinatal analysis, for identifying previously unknown regions of amplification and/or deletion, to assess the association between gene amplification and/or deletion and the extent of tumor evolution, and to identify amplification and/or deletion events that are associated with drug resistance.

ADVANTAGE - M1 enables rapid identification of only those copy number changes that occurred in most of the cells.

DESCRIPTION OF DRAWING(S) - The figure shows the general approach used in performing CGH (Comparative genomic hybridization).

Dwg.2/20

FS

CPI

FA

AB; GI; DCN

MC

CPI: **B04-E01**; B11-C07B3; B11-C08E3; B11-C08E5; **B11-C08F**  
; B12-K04A; **B12-K04F**; D05-H09; **D05-H18B**

TECH

UPTX: 20020528

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: In M1, the repetitive sequences that could bind to multiple loci in the reference metaphase chromosomes are high copy number repetitive sequences. The subject cell or cell population is derived from a clinical specimen. The subject DNA is extracted from formalin-fixed and/or paraffin-embedded archived tissue specimens. The copy number of a subject DNA sequence binding at one position in the reference metaphase chromosomes relative to the copy number of a sequence binding at another position is quantified by measuring the ratio of the signal intensities at the 2 locations. M1 further comprises the addition of an unlabeled nucleic acid to the hybridization mixture, where the unlabeled nucleic acid has a sufficient number of nucleic acid sequences substantially complementary to the sequences in the reference metaphase chromosomes to prevent saturation of the binding sites in the reference metaphase chromosomes by the labeled subject DNA. The reference metaphase chromosomes are human and prehybridized with human genomic DNA and/or human genomic DNA enriched in high copy repetitive sequences, and are included in the hybridization. The labeled subject DNA is tumor or fetal DNA.

ABEX

UPTX: 20020528

EXAMPLE - Comparative genomic hybridization (CGH) to identify and map increases in DNA sequence copy number in 15 breast cancer cell lines was as follows. 15 breast cancer cell lines such as BT-20, BT-474, BT-483, MCF7, MDA-157, MDA-175, MDA-231, MDA-330, MDA-361, MDA-435, MDA-436, MDA-453, SK-BR-3, ZR-75-1, ZR-75-30 were obtained. The cells were grown, trypsinized, suspended in a digestion buffer, incubated and high molecular weight DNA was extracted. DNA was also isolated from the peripheral blood of 7 normal healthy individuals. One of these was used as the normal reference DNA in all CGH hybridizations. The target metaphase slides were prepared from PHA-stimulated peripheral blood lymphocytes from a normal male. To assess the hybridization characteristics, each batch of slides was extensively tested with labeled normal genomic DNA and with whole-chromosome painting probes. CGH was performed essentially as described above. DNA samples were labeled either with biotin-14-dATP (test samples) or digoxigenin-11-dUTP (normal reference DNA). 60-100 ng of each of the labeled probes and 5 microg of unlabeled Cot-1 DNA were precipitated. The DNAs were dissolved in 10 microl of hybridization buffer. Metaphase slides were denatured, dehydrated, treated with proteinase K and dehydrated again. The hybridization mixture was applied on slides and hybridized and after hybridization, the slides were washed. Biotinylated DNA was detected with 5 microg/ml Avidin-fluorescein isothiocyanate (FITC) and digoxigenin-labeled DNA with 1 microg/ml anti-digoxigenin Rhodamine. The hybridization were analyzed using a digital image analysis system. 5 metaphases from each hybridization were analyzed for the chromosomal locations of DNA sequence increases. These regions were determined using green to red fluorescence intensity ratio profiles and information was gained during visual inspection of the



digital images. Criteria used to define the increased DNA sequence copy number in tumors were based on comparisons of normal DNAs labeled and stained with 2 different colors. These included green to red ratios that exceeded 1.25 or small paired spots of green fluorescence clearly above the background. High-level increases were defined as those chromosomal subregions where the green to red ratio exceeded 1.75. Increases that were not systematically present in all metaphases or that were seen only in one chromatid or in one of the 2 chromosome homologs were considered non-specific and were excluded from analysis. Interpretation of CGH data was guided by control experiments. Comparisons among 7 normal DNA specimens were used to establish normal levels of green to red fluorescence intensity ratio variation along the length of all human chromosomes while cell lines with known amplifications were used to assess sensitivity. 4-6 breast cancer cell lines with known ERBB2 amplification and 3 of 5 with known BCL1 amplification showed evidence of increased copy number by CGH at 17q12 and 11q13, as expected. All high level amplifications were detected by CGH, while those of a lower level were missed. No false positive ERBB2 or BCL1 amplifications were seen.

L25 ANSWER 3 OF 8 WPIX (C) 2003 THOMSON DERWENT  
 AN 2002-114358 [15] WPIX  
 DNC C2002-035107  
 TI New method of comparing test and reference genome in identifying rearrangement in tumor genomes comprising sequencing the ends of obtained inserts from the test genome and comparing the co-linearity of the ends with corresponding sequences.  
 DC B04 D16  
 IN COLLINS, C; GRAY, J W; VOLIK, S  
 PA (REGC) UNIV CALIFORNIA  
 CYC 96  
 PI WO 2001092558 A2 20011206 (200215)\* EN 38p C12Q000-00 <--  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
 NL OA PT SD SE SL SZ TR TZ UG ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR  
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU  
 SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
 AU 2001075110 A 20011211 (200225) C12Q000-00  
 ADT WO 2001092558 A2 WO 2001-US17757 20010531; AU 2001075110 A AU 2001-75110  
 20010531  
 FDT AU 2001075110 A Based on WO 200192558  
 PRAI US 2000-586529 20000531  
 IC ICM C12Q000-00  
 AB WO 200192558 A UPAB: 20020306  
 NOVELTY - Comparing, (M1), a test genome to a reference genome involves generating or obtaining a large insert vector library from a test genome, sequencing the ends of the inserts in the library and comparing the co-linearity of the sequenced ends in the library with corresponding sequences within a substantially sequenced reference genome, is new.  
 DETAILED DESCRIPTION - Comparing, M1, a test genome to a reference genome comprising:  
 (i) providing several clones of known size that covers at least a portion of the test genome;  
 (ii) obtaining sequence information from the termini of each of the clone thus obtaining a pair of terminal sequences;  
 (iii) identifying a pair of sequences within the reference genome that corresponds to each of the pairs of the terminal sequences; and  
 (iv) determining the relationship between the members of each pair of corresponding sequences within the reference genome.  
 A pair of terminal sequences is also obtained by obtaining a subset of the clones, fractionating the clones inserts, generating several subclones and obtaining sequence information from each of the subclones. A difference in the observed relationship between the members of any of the

pairs of corresponding sequences within the reference genome and the expected relationship based upon the known size of the clones indicates the presence of a rearrangement in the test genome compared to the reference genome.

USE - For identifying rearrangement in tumor genomes and for determining genetic differences between closely related species as well as between different strains of the same species.

ADVANTAGE - The method rapidly identifies rearrangements within test genomes e.g. a tumor genome in comparison with a substantially-sequenced reference genome. The method represents a major improvement over previous methods in terms of efficiency, rapidity and cost-effectiveness.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: **B04-E01; B04-E05; B04-F0100E; B04-F02A;**  
**B11-C08F; B12-K04A1; B12-K04E; D05-H09; D05-H12;**  
**D05-H12D1; D05-H14B2; D05-H18**

TECH UPTX: 20020306

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: The method further involves determining the sequence of the test genome over a region spanning at least one breakpoint of the rearrangement. The clones cover substantially all the test genome. The method further involves determining the frequency of each of the terminal sequences within the clones where an increased or decreased relative frequency of the terminal sequences indicates the presence of amplification or deletion in the test genome that includes the terminal sequence. Preferred Genome: The reference and the test genomes are from different species. The reference genome is a human genome. The test genome is from tumor cell. The terminal sequences are determined by automated sequencing. The pairs of terminal sequences from the test genome are compared to the pairs of corresponding sequence within the reference genome using a computer. Preferred Members: The members of at least one pair of corresponding sequences within the reference genome are closer together or apart than expected based on the known size of the clones, indicating the presence of an insertion or deletion respectively in the test genome between the pair of terminal sequences corresponding to the at least one pair of corresponding sequence. The members of at least one pair of corresponding sequences within the reference genome are present on different chromosomes within the reference genome, indicating the presence of a translocation in the test genome between the pair of terminal sequences corresponding to the at least one pair of corresponding sequences. Preferred Clones: The clones are BAC or PAC clones. The clones represent a redundancy of at least about 10 (preferably 20) fold of the test genome or the portion of the test genome. The clones contain at least about 100000 (preferably 200000, particularly 250000) clones. The subclones represent a redundancy of 0.001 - 5 (preferably 0.01 - 1, more preferably 0.05 - 0.5, particularly 0.1) fold of the subset of the clones. Preferred Sequences: The terminal sequences are present on average between about 5 - 500 (preferably at most 50, more preferably at most 10, particularly at most 5) kb throughout the test genome or the portion of the test genome. The sequence is obtained from the termini of each of the subclones.

ABEX UPTX: 20020306

EXAMPLE - No relevant example given.

L25 ANSWER 4 OF 8 WPIX (C) 2003 THOMSON DERWENT

AN 2002-114015 [15] WPIX

DNN N2002-085067 DNC C2002-034865

TI A new software tool for integration and presentation of repeat and CpG dinucleotide distribution in a DNA sequence provides a graphical output useful in functional genomic analysis.

DC B04 D16 P85 T01

IN COLLINS, C; GRAY, J W; VOLIK, S

PA (REGC) UNIV CALIFORNIA

CYC 94

PI WO 2001075856 A1 20011011 (200215)\* EN 20p G09G005-36 <--  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
 NL OA PT SD SE SL SZ TR TZ UG ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
 DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
 LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD  
 SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AU 2001049701 A 20011015 (200215) G09G005-36

ADT WO 2001075856 A1 WO 2001-US10399 20010330; AU 2001049701 A AU 2001-49701  
 20010330

FDT AU 2001049701 A Based on WO 200175856

PRAI US 2000-541438 20000331

IC ICM G09G005-36

ICS **C12Q001-68**

AB WO 200175856 A UPAB: 20020306

NOVELTY - Analyzing and displaying on a digital computer a sequence of base pairs, and plotting descriptive information regarding the sequence, is new.

DETAILED DESCRIPTION - Analyzing and displaying on a digital computer a sequence comprising a list of base pairs, and plotting descriptive information regarding the sequence comprises:

- (a) executing a process to identify repeat sequences in the sequence;
- (b) plotting an axis corresponding to the sequence base pairs, in windows of specified number of base pair units; and
- (c) for each window, plotting along a second axis an indication of the portion of the base pairs included in the window that comprise repeat sequences.

INDEPENDENT CLAIMS are also included for the following:

- (1) visualizing features of a nucleotide sequence, comprising:
  - (a) dividing the sequence into contiguous windows with a width of chosen numbers of base pairs;
  - (b) analyzing the sequence to identify repeat data;
  - (c) generating repeat frequency information in each window;
  - (d) generating CpG frequency output files for each window;
  - (e) providing a masked sequence having repeat data masked from the sequence;
  - (f) selecting a sequence database including previously determined sequences;
  - (g) comparing the masked sequence to the database to create a database hit output file identifying regions of the sequence database that align with portions of the masked sequence;
  - (h) analyzing the database output files to create a list of the number of relevant hits for each window;
  - (i) capturing those hits which extend over length and identity over a selected threshold of base pairs and generating annotation data;
  - (j) gathering repeat information from the repeat output files, annotation and distribution of database hits and producing a graphical summary for display or reproduction; and
  - (k) plotting frequency of CpG and gene-indicating sequences on the summary;
- (2) visually displaying selected information about a DNA sequence comprising:
  - (a) analyzing the sequence to identify regions of repeat data;
  - (b) using the identified regions to form a masked sequence;
  - (c) performing an alignment search of the masked sequence on a selected sequence database to generate alignment information;
  - (d) analyzing the alignment information to determine regions of correspondence of a specified type;
  - (e) plotting graphical regions indicating the correspondence;
  - (f) analyzing the sequence data to determine frequency of selected nucleotide pairs; and
  - (g) graphically indicating the above frequency and the proportion of

the window containing the repeat data;

(3) a computer program visualizing important features of a genome sequence for processing repeat data and indicating regions of correspondence between sequences in a database comprising code for carrying out the processes as detailed in the disclosure.

USE - The software is used in the functional interpretation of DNA sequences especially the number of short interspersed repetitive elements, long interspersed repetitive elements, long terminal repeats, DNA elements, satellites, simple repeats and low complexity regions.

ADVANTAGE - Unlike prior art programs the output is in graphical form, compressing 400-500 pages of text output to 4-5 pages of easy to analyze graphical summary.

Dwg.0/3

FS CPI EPI GMPI

FA AB; DCN

MC CPI: **B04-E01**; B11-C08E5; **B12-K04F**; D05-H09;  
D05-H12

EPI: **T01-J05B2**; **T01-J05B4P**; **T01-J12B1**;  
**T01-S03**

TECH UPTX: 20020306

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: The method preferably includes a second process to determine frequency of occurrence in each window of a specified nucleotide pair, particularly CpG dinucleotides, and plotting their frequency. The first process preferably includes determining the number of short interspersed repetitive elements, long interspersed repetitive elements, long terminal repeats, DNA elements, satellites, simple repeats and low complexity regions, and plotting each number.

ABEX UPTX: 20020306

EXAMPLE - No suitable example is given.

L25 ANSWER 5 OF 8 WPIX (C) 2003 THOMSON DERWENT

AN 2000-224375 [19] WPIX

DNC C2000-068544

TI Identification of novel amplicons in human chromosome 20 for diagnosis and prognosis of cancers, particularly breast cancer, involves hybridization of a probe specific for this region.

DC B04 D16

IN ALBERTSON, D; **COLLINS, C**; **GRAY, J**; PINKEL, D;  
ALBERTSON, D G; **GRAY, J W**

PA (REGC) UNIV CALIFORNIA; (ALBE-I) ALBERTSON D G; (COLL-I) COLLINS C;  
(GRAY-I) GRAY J W; (PINK-I) PINKEL D

CYC 22

PI WO 2000009758 A1 20000224 (200019)\* EN 48p C12Q001-68 <--

RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

W: CA JP

EP 1112379 A1 20010704 (200138) EN C12Q001-68 <--

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

US 2002120526 A1 20020829 (200259) G06F017-60 <--

JP 2002522097 W 20020723 (200263) 64p C12Q001-68 <--

ADT WO 2000009758 A1 WO 1999-US18483 19990812; EP 1112379 A1 EP 1999-941131  
19990812, WO 1999-US18483 19990812; US 2002120526 A1 Div ex US 1998-134044  
19980814, US 2001-896070 20010628; JP 2002522097 W WO 1999-US18483  
19990812, JP 2000-565192 19990812

FDT EP 1112379 A1 Based on WO 200009758; JP 2002522097 W Based on WO 200009758

PRAI US 1998-134044 19980814; US 2001-896070 20010628

IC ICM **C12Q001-68**; **G06F017-60**

ICS C12N015-09; G01N033-53; G01N033-566; G01N037-00

AB WO 200009758 A UPAB: 20000419

NOVELTY - Screening for an amplicon in a sample human nucleic acid (A) comprises detecting a hybridization complex formed by contacting (A) with a probe that specifically hybridizes to a nucleic acid sequence (I) including D20S211 through D20S120.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a nucleic acid probe comprising a sequence which specifically hybridizes to (I); and

(2) a kit for screening the presence of an amplicon comprising (I) comprising probes as in (1).

USE - The screening methods are useful for identifying amplicons in a human nucleic acid sample which are used for diagnosing and prognosing cancers, particularly breast cancers.

DESCRIPTION OF DRAWING(S) - The figure shows the results of an analysis of the 20q13.2 region of a tumor (S21) using hybridoma analysis. The graphs show comparative genomic hybridization (CGH) ratios for selected 20q13.2 clones in tumor S21, indicating the G/R or green (fluorescein dCTP) to red (Texas red dCTP) fluorescence ratio as a function of the amount of genomic nucleic acid hybridization to the 20q13.2 contig clones.

Dwg.1/3

FS CPI

FA AB; GI; DCN

MC CPI: **B04-E05**; B11-C08E5; B12-K04E; **B12-K04F**;  
**D05-H12D1**; **D05-H18B**

TECH UPTX: 20000419

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: The human nucleic acid is genomic DNA isolated from breast tumor cells. Detection further involves determining the copy number of the amplicon. (A) and (I) are labeled with a detectable composition (preferably fluorescein or Texas red for (A)). The method further comprises providing a nucleic acid from a reference cell which is contacted with the probe before or simultaneously with (A) and/or hybridizing CotI DNA to (A) before contacting (A) with (I).

Preferred Nucleic Acid: (I) comprises a Genome Database (GDB) locus nucleic acid sequence (Ia) (comprising 1 of 7 sequences named in the specification, e.g. D20S211), a cloned genomic nucleic acid sequence (Ib) (comprising 1 of 16 sequences named in the specification, e.g. RMC20B4097) or a polymerase chain reaction primer pair comprising STS marker sequence (Ic) (comprising 1 of 10 sequences named in the specification, e.g. AFMa233wgl). (I) is preferably attached to solid surface as a member of a nucleic acid array.

ABEX UPTX: 20000419

SPECIFIC OLIGONUCLEOTIDES - (I) comprises a Genome Database (GDB) locus nucleic acid sequence (Ia), a cloned genomic nucleic acid sequence (Ib), or a polymerase chain reaction primer pair comprising STS marker sequence (Ic).

(Ia) is D20S211, D20S854, D20S876, D20S1044, D20S913, D20S720 and D20S120. (Ib) is RMC20B4097, RMC20B4103, RMC20P4016, RMC20B4130, RMC20P4185, RMC20B4188, RMC20B4109, RMC20P4010, RMC20P4028, RMC20P4003, RMC20B4099, RMC20P4018, RMC20P4069, RMC20B4121, RMC20B4087 and RMC20P4070. (Ic) is AFMa233wgl, AFM080yal, AFM069yal, WI-16748, WI-9939, AFMa072zb9, WI-6578, AFM224zd12, WI-9227 and AFM276xh1 (claimed).

EXAMPLE - Nucleic acid from breast tissue was used to prepare labeled biological sample, the cloned genomic DNA use as probes was produced by standard recombinant technology. A standard hybridization reaction was performed using fluorescein labeled human nucleic acid and Texas red labeled DNA. After hybridization the slide was washed and placed in an array apparatus for reading fluorescence. The data obtained from the intensities of two fluorochromes was calculated for each target and the data was transmitted for storage and analysis by an image analysis program.

L25 ANSWER 6 OF 8 WPIX (C) 2003 THOMSON DERWENT

AN 1999-579905 [49] WPIX

CR 1991-165919 [23]; 1992-217417 [27]; 1992-286380 [35]; 1993-303497 [38];

1995-319885 [41]; 1999-037064 [04]; 1999-105095 [09]; 1999-619646 [53];  
2001-564345 [63]; 2002-163200 [21]; 2002-303417 [34]; 2003-352179 [33];  
2003-352608 [33]

DNC **C1999-168669**

TI Detecting an amplification of sequences using comparative genomic hybridization.

DC B04 D16

IN **GRAY, J W**; KALLIONIEMI, A; KALLIONIEMI, O; PINKEL, D; SAKAMOTO, M; WALDMAN, F

PA (REGC) UNIV CALIFORNIA

CYC 1

PI US 5965362 A 19991012 (199949)\* 54p C12Q001-68

ADT US 5965362 A CIP of US 1992-846659 19920304, CIP of US 1992-969948 19921030, Cont of US 1993-132172 19931006, Div ex US 1994-223905 19940406, US 1995-562965 19951127

PRAI US 1993-132172 19931006; US 1992-846659 19920304; US 1992-969948 19921030; US 1994-223905 19940406; US 1995-562965 19951127

IC ICM C12Q001-68

ICS A61K049-00; C07H021-02; C12P019-34

AB US 5965362 A UPAB: 20030526

NOVELTY - A method, known as comparative genomic hybridization (CGH), to compare the copy numbers of different DNA/RNA sequences from a sample by using kinetics of in situ hybridization, is new.

DETAILED DESCRIPTION - The method, which involves detecting an amplification of unique sequences of at least one position selected from position q24 of human chromosome 8, about position q13 of human chromosome 11 or about position q22-q24 of human chromosome 17 or at least one chromosome arm consisting of the q arm of chromosome 1, 8 or 20 in a genome being tested, comprises:

(a) differentially labeling DNA sequences from the test genome and a normal human genome;

(b) hybridizing the labeled DNA sequences from each of the genomes to a reference genome under the following conditions:

(i) either the labeled DNA sequences or the reference genome, or both, have their repetitive sequences blocked and/or removed;

(ii) DNA unique sequences in the reference genome are retained; and

(c) comparing the intensities of the signals from the labeled DNA sequences as a function of position on the reference genome, therefore allowing detection of the presence or absence of the amplification in the test genome.

USE - CGH is used to determine the relative number of copies of nucleic acid sequences in one or more subject genomes (e.g. DNA of tumor cells) or their portions as a function of the location of those sequences in a reference genome.

ADVANTAGE - CGH determines whether there are abnormal copy numbers of nucleic acid sequences anywhere in the genome of the subject tumor cell or fetal cell without having to prepare condensed chromosome spreads from those cells. CGH also facilitates the genetic analysis of tumors much quicker than prior art methods.

Dwg.0/20

FS CPI

FA AB; DCN

MC CPI: **B04-E01**; B11-C07B3; B11-C08E3; B11-C08E5; **B12-K04F**; D05-H09; **D05-H18B**

TECH UPTX: 19991124

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: The method comprises determining the ratio of the intensities of the signals as a function of position in the reference genome. When detecting amplification of unique sequences, the amplification is detected at position q24 of chromosome 8, about position q13 of human chromosome 11 or about position q22-q24 of human chromosome 17 in the test genome. When detecting amplification of the chromosome arm, the amplification is of the q arm of human chromosome 1, 8 or 20. The reference genome comprises at least one metaphase

chromosome.

ABEX

UPTX: 19991124

EXAMPLE - 11 cell lines and 2 primary tumor DNAs were labeled with biotin-14-dATP or digoxigenin-11-dUTP by nick translation. The optimal size for double stranded probe fragments after labeling was 600-1000 bp. Sixty ng of biotinylated test DNA, 60 ng of digoxigeninlabeled normal DNA and 5 ng of unlabeled Cot-1 DNA were ethanol precipitated and dissolved in 10 microl of 50% formamide, 10% dextran sulfate, 2 x SSC, pH 7. The probe mixture was denatured at 70 degrees Centigrade for 5 minutes, allowed to reanneal at 37 degrees Centigrade for 60 minutes and hybridized to normal male metaphase chromosomes for 3-4 days at 37 degrees Centigrade. Immunofluorescent probe detection was carried out at room temperature in three thirty minute steps using 5 microg/ml anti-avidin, 5 microg/ml FITC-avidin and 2 microg/ml anti-digoxigenin-Rhodamine. Nuclei were counterstained with 0.8 microM 4,5-diamino-2-phenylindole (DAPI) in antifade solution. A Zeiss fluorescence microscope equipped with a double band pass filter was used for simultaneous visualization of FITC and rhodamine signals. Analysis of tumor cell lines and primary bladder tumors identified 16 different regions of amplification, many in loci not previously known to be amplified. In 5 of the 11 cell lines, more than one locus was amplified. 2 or 3 separate loci on the same chromosome were amplified in 4 cell lines which suggests a spatial clustering of chromosome locations that undergo DNA amplification.

L25 ANSWER 7 OF 8 WPIX (C) 2003 THOMSON DERWENT

AN 1996-287201 [29] WPIX

DNC C1996-091906

TI Comparing copy number of nucleic acid sequences - by comparative hybridisation of differentially labelled nucleic acids to target elements on a solid support.

DC B04 D16 T01

IN ALBERTSON, D; GRAY, J W; PINKEL, D

PA (MEDI-N) MEDICAL RES COUNCIL; (REGC) UNIV CALIFORNIA; (ALBE-I) ALBERTSON D; (GRAY-I) GRAY J W; (PINK-I) PINKEL D

CYC 20

PI WO 9617958 A1 19960613 (199629)\* EN 33p C12Q001-68 <--

RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

W: CA JP

EP 800587 A1 19971015 (199746) EN C12Q001-68 <--

R: AT BE CH DE DK ES FR GB IE IT LI NL SE

US 5830645 A 19981103 (199851) C12N001-68

JP 11510681 W 19990921 (199950) 29p C12Q001-68 <--

US 2003008318 A1 20030109 (200311) C12Q001-68 <--

US 6562565 B1 20030513 (200335) C12Q001-68 <--

ADT WO 9617958 A1 WO 1995-US16155 19951208; EP 800587 A1 EP 1995-943084 19951208; WO 1995-US16155 19951208; US 5830645 A US 1994-353018 19941209; JP 11510681 W WO 1995-US16155 19951208; JP 1996-517815 19951208; US 2003008318 A1 Div ex US 1994-353018 19941209, Cont of US 1996-670953 19960626, US 2002-229158 20020828; US 6562565 B1 Cont of US 1994-353018 19941209, US 1996-670953 19960626

FDT EP 800587 A1 Based on WO 9617958; JP 11510681 W Based on WO 9617958; US 2003008318 A1 Div ex US 5830645; US 6562565 B1 Cont of US 5830645

PRAI US 1994-353018 19941209; US 1996-670953 19960626; US 2002-229158 20020828

REP 04Jnl.Ref; US 4981783; US 5028525; US 5194300; US 5447841; WO 9318186

IC ICM C12N001-68; C12Q001-68

ICS C07H019-04; C07H021-04; C12N015-09; C12P019-34; G01N033-566; G06K009-40; G06K009-58; G06K009-60; G06T001-00; G06T001-40

AB WO 9617958 A UPAB: 19960724

A method is claimed for comparing copy number of nucleic acid (NA) sequences in collections of 2 NA mols., comprising: (a) providing target elements bound to a solid surface, each target element comprising a target NA, (b) contacting the target elements with: (i) a first collection of

labelled NAs comprising a sequence complementary to a target nucleotide sequence and (ii) 1 second labelled NA comprising a sequence complementary to the target nucleotide sequence, where the first and second labels are distinguishable from each other and (c) detecting the amt. of binding of the first and second labelled complementary NAs to the target NAs.

Also claimed is a kit for quantitating NA sequences in a NA sample, comprising: (a) a solid support having an array of preselected target NAs bound to it, where the array has 2 members, and (b) a container contg. reference NAs which comprise sequences that are complementary and non-complementary to 1 member of the array.

USE - The method is used for comparing abnormal NA copy number and to detect and mapping chromosomal abnormalities associated with diseases such as tumours.

ADVANTAGE - Using the method, the resolution with which copy number change can be mapped is > 10 times better than with standard comparative genomic hybridisation (CGH). This improved localisation facilitates efforts to identify the critical genes involved in a disease and permits more sensitive detection of abnormalities involving a small region of a genome such as in micro-deletion syndromes.

Dwg.0/1

FS CPI EPI

FA AB

MC CPI: B11-C06; B11-C08E5; **B12-K04F**; D05-H09; **D05-H18**

EPI: **T01-J10C4**

L25 ANSWER 8 OF 8 WPIX (C) 2003 THOMSON DERWENT

AN **1993-303497** [38] WPIX

CR 1991-165919 [23]; 1992-217417 [27]; 1992-286380 [35]; 1995-319885 [41];  
1999-037064 [04]; 1999-105095 [09]; 1999-579905 [49]; 1999-619646 [53];  
2001-564345 [63]; 2002-163200 [21]; 2002-303417 [34]; 2003-352179 [33];  
2003-352608 [33]

DNC **C1993-135243**

TI Comparative genomic hybridisation methods - providing in situ detection of amplification(s) and deletions, useful for analysing tumour DNA and for pre-natal diagnosis, e.g. of Downs syndrome.

DC B04 D16

IN **GRAY, J W**; KALLIONIEMI, A; KALLIONIEMI, O P; PINKEL, D; WALDMAN, F; KALLIONIEMI, O; KALLIONIEMI, A P

PA (REGC) UNIV CALIFORNIA

CYC 22

PI WO 9318186 A1 19930916 (199338)\* EN 88p C12Q001-68

RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

W: AU CA JP KR

AU 9337808 A 19931005 (199405)

EP 631635 A1 19950104 (199506) EN

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

JP 07505053 W 19950608 (199531) C12Q001-68

US 5665549 A 19970909 (199742) 42p C12Q001-68

US 5721098 A 19980224 (199815) 42p C12Q001-68

US 6159685 A 20001212 (200067) C12Q001-68

EP 631635 B1 20010912 (200155) EN C12Q001-68

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

EP 1134293 A2 20010919 (200155) EN C12Q001-68

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DE 69330750 E 20011018 (200169) C12Q001-68

ES 2161715 T3 20011216 (200206) C12Q001-68

CA 2131543 C 20020917 (200267) EN C12Q001-68

CA 2392673 A1 19930916 (200271) EN C12Q001-68

ADT WO 9318186 A1 WO 1993-US1775 19930301; AU 9337808 A AU 1993-37808  
19930301; EP 631635 A1 EP 1993-907077 19930301; WO 1993-US1775 19930301;  
JP 07505053 W JP 1993-515791 19930301; WO 1993-US1775 19930301; US 5665549  
A CIP of US 1992-846659 19920304, Cont of US 1992-969948 19921030, Div ex



US 1993-166147 19931214, US 1995-466122 19950606; US 5721098 A CIP of US 1986-819314 19860116, CIP of US 1986-937793 19861204, CIP of US 1989-444669 19891201, CIP of US 1990-497098 19900320, CIP of US 1990-537305 19900612, CIP of US 1991-659974 19910222, CIP of US 1991-670242 19910315, CIP of US 1992-846659 19920304, Cont of US 1992-969948 19921030, Cont of US 1993-166147 19931214, US 1995-468629 19950606; US 6159685 A CIP of US 1986-819314 19860116, CIP of US 1986-937793 19861204, CIP of US 1989-444669 19891201, CIP of US 1990-497098 19900320, CIP of US 1990-537305 19900612, Cont of US 1990-627707 19901214, CIP of US 1991-659974 19910222, CIP of US 1991-670242 19910315, CIP of US 1992-846659 19920304, Cont of US 1992-969948 19921030, Cont of US 1993-166147 19931214, Cont of US 1995-468629 19950606, US 1997-903095 19970730; EP 631635 B1 EP 1993-907077 19930301, WO 1993-US1775 19930301, Related to EP 2001-200109 19930301; EP 1134293 A2 Div ex EP 1993-907077 19930301, EP 2001-200109 19930301; DE 69330750 E DE 1993-630750 19930301, EP 1993-907077 19930301, WO 1993-US1775 19930301; ES 2161715 T3 EP 1993-907077 19930301; CA 2131543 C CA 1993-2131543 19930301, WO 1993-US1775 19930301; CA 2392673 A1 Div ex CA 1993-2131543 19930301, CA 1993-2392673 19930301

FDT AU 9337808 A Based on WO 9318186; EP 631635 A1 Based on WO 9318186; JP 07505053 W Based on WO 9318186; US 6159685 A Cont of US 5447841, Cont of US 5721098; EP 631635 B1 Based on WO 9318186; EP 1134293 A2 Div ex EP 631635; DE 69330750 E Based on EP 631635, Based on WO 9318186; ES 2161715 T3 Based on EP 631635; CA 2131543 C Based on WO 9318186

PRAI US 1992-969948 19921030; US 1992-846659 19920304; US 1993-166147 19931214; US 1995-466122 19950606; US 1986-819314 19860116; US 1986-937793 19861204; US 1989-444669 19891201; US 1990-497098 19900320; US 1990-537305 19900612; US 1991-659974 19910222; US 1991-670242 19910315; US 1995-468629 19950606; US 1990-627707 19901214; US 1997-903095 19970730

REP 3.Jnl.Ref; EP 430402; WO 9005789

IC ICM C12Q001-68

ICS C07H021-02; C07H021-04; C12N015-09; C12P011-34; C12P019-34

AB WO 9318186 A UPAB: 20030526

Comparing copy numbers of different DNA sequences in a subject cell or cell population comprises: (a) extracting the DNA from the subject cell or from a number of cells of the subject cell population; (b) amplifying the extd. DNA, if necessary; (c) labelling the DNA; (d) hybridising the labelled DNA in situ to reference metaphase chromosomes, after removing from the labelled DNA, those repetitive sequences which could bind to multiple loci in the reference metaphase chromosomes, and/or after blocking the binding sites for those repetitive sequences in the reference metaphase chromosomes by pre-hybridisation with appropriate blocking nucleic acids, and/or blocking those repetitive sequences in the labelled subject DNA by pre-hybridisation with appropriate blocking nucleic acid sequences; (e) rendering the bound, labelled DNA sequences, visualisable, if necessary; (f) observing and/or measuring the intensity of the signal from the bound labelled DNA sequences as a function of position on the reference metaphase chromosomes; and (g) comparing the copy numbers of different DNA sequences of the subject DNA by comparing the signal intensities at different positions on the reference metaphase chromosomes, where the greater the signal intensity at a given position, the greater the copy number of the sequences in the subejct DNA which bind at that position.

USE/ADVANTAGE - The comparative genomic hybridisation (CGH) methods can be qualitative or quantitative and are partic. useful for analysing DNA sequences from cells from clinical specimens including tumour and foetal tissue. CGH may be used to detect sequence copy number imbalances throughout an entire genome in one hybridisation, to map gains and/or losses of sequences in a genome and/or to provide a copy number karyotype of a subject genome. Specific applications include early detection of amplifications and/or deletions in cells from a suspected lesion and prenatal detection of an extra copy of chromosome 21, diagnostic of Down's

Syndrome

Dwg.0/9

FS CPI

FA AB

MC CPI: **B04-B04A1**; B11-C08E; B12-K04A3; **D05-H12**

ABEQ US 5665549 A UPAB: 19971021

A method of comparing copy numbers of unique DNA sequences in a first cell or cell population relative to copy numbers of substantially identical sequences in a second cell or cell population, said method comprising the steps of:

(a) labelling genomic DNA sequences from each cell or cell population with a different label;

(b) hybridizing said labelled DNA sequences from each cell or cell population to a reference genome under the following conditions:

(i) either the labelled DNA sequences, and/or the reference genome have their repetitive sequences blocked and/or removed; and

(ii) unique DNA sequences in the labelled DNA sequences and unique DNA sequences in the reference genome are retained;

(c) comparing the intensities of the signals from the labelled DNA sequences hybridized to the reference genome.

Dwg.0/13

ABEQ US 5721098 A UPAB: 19980410

Comparing copy numbers of different DNA sequences in a subject cell or cell population comprises: (a) extracting the DNA from the subject cell or from a number of cells of the subject cell population; (b) amplifying the extd. DNA, if necessary; (c) labelling the DNA; (d) hybridising the labelled DNA in situ to reference metaphase chromosomes, after removing from the labelled DNA, those repetitive sequences which could bind to multiple loci in the reference metaphase chromosomes, and/or after blocking the binding sites for those repetitive sequences in the reference metaphase chromosomes by pre-hybridisation with appropriate blocking nucleic acids, and/or blocking those repetitive sequences in the labelled subject DNA by pre-hybridisation with appropriate blocking nucleic acid sequences; (e) rendering the bound, labelled DNA sequences, visualisable, if necessary; (f) observing and/or measuring the intensity of the signal from the bound labelled DNA sequences as a function of position on the reference metaphase chromosomes; and (g) comparing the copy numbers of different DNA sequences of the subject DNA by comparing the signal intensities at different positions on the reference metaphase chromosomes, where the greater the signal intensity at a given position, the greater the copy number of the sequences in the subejct DNA which bind at that position.

USE/ADVANTAGE - The comparative genomic hybridisation (CGH) methods can be qualitative or quantitative and are partic. useful for analysing DNA sequences from cells from clinical specimens including tumour and foetal tissue. CGH may be used to detect sequence copy number imbalances throughout an entire genome in one hybridisation, to map gains and/or losses of sequences in a genome and/or to provide a copy number karyotype of a subject genome. Specific applications include early detection of amplifications and/or deletions in cells from a suspected lesion and prenatal detection of an extra copy of chromosome 21, diagnostic of Down's Syndrome

Dwg.0/13

=> fil dpci

FILE 'DPCI' ENTERED AT 14:10:25 ON 16 JUL 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE LAST UPDATED: 14 JUL 2003 <20030714/UP>

PATENTS CITATION INDEX, COVERS 1973 TO DATE

>>> LEARNING FILE LDPCI AVAILABLE <<<

=&gt; d all

L26 ANSWER 1 OF 1 DPCI COPYRIGHT 2003 THOMSON DERWENT  
 AN 2002-114358 [15] DPCI  
 DNC C2002-035107  
 TI New method of comparing test and reference genome in identifying  
 rearrangement in tumor genomes comprising sequencing the ends of obtained  
 inserts from the test genome and comparing the co-linearity of the ends  
 with corresponding sequences.  
 DC B04 D16  
 IN COLLINS, C; GRAY, J W; VOLIK, S  
 PA (REGC) UNIV CALIFORNIA  
 CYC 96  
 PI WO 2001092558 A2 20011206 (200215)\* EN 38p C12Q000-00 <--  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
 NL OA PT SD SE SL SZ TR TZ UG ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR  
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU  
 SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
 AU 2001075110 A 20011211 (200225) C12Q000-00  
 ADT WO 2001092558 A2 WO 2001-US17757 20010531; AU 2001075110 A AU 2001-75110  
 20010531  
 FDT AU 2001075110 A Based on WO 200192558  
 PRAI US 2000-586529 20000531  
 IC ICM C12Q000-00  
 FS CPI

## CTCS CITATION COUNTERS

PNC.DI	0	Cited Patents Count (by inventor)
PNC.DX	2	Cited Patents Count (by examiner)
IAC.DI	0	Cited Issuing Authority Count (by inventor)
IAC.DX	1	Cited Issuing Authority Count (by examiner)
PNC.GI	0	Citing Patents Count (by inventor)
PNC.GX	0	Citing Patents Count (by examiner)
IAC.GI	0	Citing Issuing Authority Count (by inventor)
IAC.GX	0	Citing Issuing Authority Count (by examiner)
CRC.I	0	Cited Literature References Count (by inventor)
CRC.X	1	Cited Literature References Count (by examiner)

CDP CITED PATENTS UPD: 20030709

## Cited by Examiner

CITING PATENT	CAT	CITED PATENT	ACCNO
WO 200192558	A X	US 5830645	A 1996-287201/29
PA:		(MEDI-N) MEDICAL RES COUNCIL; (REGC) UNIV CALIFORNIA; (ALBE-I) ALBERTSON D; (GRAY-I) GRAY J W; (PINK-I) PINKEL D	
IN:		ALBERTSON, D; GRAY, J W; PINKEL, D	
X		US 6013439	A 1997-351081/32
PA:		(BEHW) BEHRINGWERKE AG; (ULLM-I) ULLMAN E; (ULLM-I) ULLMAN E F; (KURN-I) KURN N; (LISH-I) LISHANSKI A; (DADE-N) DADE BEHRING MARBURG GMBH	
IN:		KURN, N; LISHANSKI, A; ULLMAN, E F	

REN LITERATURE CITATIONS UPR: 20030709

## Citations by Examiner

CITING PATENT	CAT	CITED LITERATURE
WO 200192558	A	ALTSCHUL S.F. ET AL.: 'Basic local alignment tool' J. MOL. BIOL. vol. 215, 05 October 1990, pages 403 - 410, XP002949123

=&gt; fil wpix

FILE 'WPIX' ENTERED AT 14:11:35 ON 16 JUL 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE LAST UPDATED: 10 JUL 2003 <20030710/UP>  
 MOST RECENT DERWENT UPDATE: 200344 <200344/DW>  
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

&gt;&gt;&gt; NEW WEEKLY SDI FREQUENCY AVAILABLE --&gt; see NEWS &lt;&lt;&lt;

>>> SLART (Simultaneous Left and Right Truncation) is now  
 available in the /ABEX field. An additional search field  
 /BIX is also provided which comprises both /BI and /ABEX <<<

&gt;&gt;&gt; PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY &lt;&lt;&lt;

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,  
 SEE <http://www.derwent.com/dwpi/updates/dwpicov/index.html> <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
 PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
 GUIDES, PLEASE VISIT:  
[http://www.derwent.com/userguides/dwpi\\_guide.html](http://www.derwent.com/userguides/dwpi_guide.html) <<<

=&gt; d all abeq tech abex

L28 ANSWER 1 OF 1 WPIX (C) 2003 THOMSON DERWENT  
 AN 1997-351081 [32] WPIX  
 DNN N1997-290911 DNC C1997-113482  
 TI Detection of differences in related nucleic acids - comprises forming a  
 complex of the DNA and detecting the presence of the complex.  
 DC B04 D16 S03  
 IN KURN, N; LISHANSKI, A; ULLMAN, E F  
 PA (BEHW) BEHRINGWERKE AG; (ULLM-I) ULLMAN E; (ULLM-I) ULLMAN E F; (KURN-I)  
 KURN N; (LISH-I) LISHANSKI A; (DADE-N) DADE BEHRING MARBURG GMBH  
 CYC 23  
 PI WO 9723646 A1 19970703 (199732)\* EN 96p C12Q001-68  
 RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
 W: AU CA JP KR MX  
 AU 9715653 A 19970717 (199745) C12Q001-68  
 EP 920532 A1 19990609 (199927) EN C12Q001-68  
 R: AT BE DE FR GB IT NL  
 US 6013439 A 20000111 (200010) C12Q001-68 <--  
 US 2001014450 A1 20010816 (200149) C12Q001-68  
 US 6555317 B2 20030429 (200331) C12Q001-68  
 ADT WO 9723646 A1 WO 1996-US19750 19961220; AU 9715653 A AU 1997-15653  
 19961220; EP 920532 A1 EP 1996-945386 19961220, WO 1996-US19750 19961220;

US 6013439 A Provisional US 1995-9289P 19951222, Provisional US 1996-12929P 19960306, US 1996-771623 19961220; US 2001014450 A1 Provisional US 1995-9289P 19951222, Provisional US 1996-12929P 19960306, Cont of US 1996-771623 19961220, Cont of US 1999-370919 19990809, US 2000-732279 20001207; US 6555317 B2 Provisional US 1995-9289P 19951222, Provisional US 1996-12929P 19960306, Cont of US 1996-771623 19961220, Cont of US 1999-370919 19990809, US 2000-732279 20001207

FDT AU 9715653 A Based on WO 9723646; EP 920532 A1 Based on WO 9723646; US 2001014450 A1 Cont of US 6013439; US 6555317 B2 Cont of US 6013439

PRAI US 1996-12929P 19960306; US 1995-9289P 19951222; US 1996-771623 19961220; US 1999-370919 19990809; US 2000-732279 20001207

REP 3.Jnl.Ref; EP 450370; EP 469755; WO 9403812

IC ICM C12Q001-68  
ICS C07H021-00; C07H021-02; C12P019-34; G01N033-58

AB WO 9723646 A UPAB: 19970806  
Methods for the detection of differences in related nucleic acid sequences are claimed.  
USE - The methods provide detection of any differences in two related nucleic acid sequences, whether differences are known or not. These methods are simple, inexpensive and sensitive for detecting mutations, and are suitable for large scale population screenings.  
Dwg.0/9

FS CPI EPI  
FA AB  
MC CPI: B04-E01; B11-C08E3; B12-K04F; D05-H09  
EPI: S03-E14H9

=> fil medline

FILE 'MEDLINE' ENTERED AT 14:12:55 ON 16 JUL 2003

FILE LAST UPDATED: 15 JUL 2003 (20030715/UP). FILE COVERS 1958 TO DATE.

On April 13, 2003, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/changes2003.html> for a description on changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all

L29 ANSWER 1 OF 1 MEDLINE  
AN 91039304 MEDLINE  
DN 91039304 PubMed ID: 2231712  
TI Basic local alignment search tool.  
AU **Altschul S F**; Gish W; Miller W; Myers E W; Lipman D J  
CS National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894.  
NC LM04960 (NLM)  
LM05110 (NLM)  
SO JOURNAL OF MOLECULAR BIOLOGY, (1990 Oct 5) 215 (3) 403-10.  
Journal code: 2985088R. ISSN: 0022-2836.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199012  
ED Entered STN: 19910208  
Last Updated on STN: 19910208

Entered Medline: 19901205

AB A new approach to rapid sequence comparison, basic local alignment search tool (BLAST), directly approximates alignments that optimize a measure of local similarity, the maximal segment pair (MSP) score. Recent mathematical results on the stochastic properties of MSP scores allow an analysis of the performance of this method as well as the statistical significance of alignments it generates. The basic algorithm is simple and robust; it can be implemented in a number of ways and applied in a variety of contexts including straightforward DNA and protein sequence database searches, motif searches, gene identification searches, and in the analysis of multiple regions of similarity in long DNA sequences. In addition to its flexibility and tractability to mathematical analysis, BLAST is an order of magnitude faster than existing sequence comparison tools of comparable sensitivity.

CT Check Tags: Support, U.S. Gov't, P.H.S.

Algorithms

Amino Acid Sequence

\*Base Sequence

Databases, Factual

\*Mutation

Sensitivity and Specificity

Sequence Homology, Nucleic Acid

\*Software

=> fil medline

FILE 'MEDLINE' ENTERED AT 16:21:59 ON 15 JUL 2003

FILE LAST UPDATED: 13 JUL 2003 (20030713/UP). FILE COVERS 1958 TO DATE.

On April 13, 2003, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/changes2003.html> for a description on changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot

L64 ANSWER 1 OF 10 MEDLINE  
AN 2003297305 IN-PROCESS  
DN 22709111 PubMed ID: 12788976  
TI **End-sequence profiling: sequence-based analysis of aberrant genomes.**  
AU **Volik Stanislav; Zhao Shaying; Chin Koei; Brebner John H; Herndon David R; Tao Quanzhou; Kowbel David; Huang Guiqing; Lapuk Anna; Kuo Wen-Lin; Magrane Gregg; De Jong Pieter; Gray Joe W; Collins Colin**  
CS Cancer Research Institute and Department of Laboratory Medicine, University of California Comprehensive Cancer Center, 2340 Sutter Street, San Francisco, CA 94115, USA.  
NC CA58207 (NCI)  
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (2003 Jun 24) 100 (13) 7696-701.  
Journal code: 7505876. ISSN: 0027-8424.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS IN-PROCESS; NONINDEXED; Priority Journals  
OS GENBANK-BZ597614; GENBANK-BZ597615; GENBANK-BZ597616; GENBANK-BZ597617; GENBANK-BZ597618; GENBANK-BZ597619; GENBANK-BZ597620; GENBANK-BZ597621; GENBANK-BZ597622; GENBANK-BZ597623; GENBANK-BZ597624; GENBANK-BZ597625; GENBANK-BZ597626; GENBANK-BZ597627; GENBANK-BZ597628; GENBANK-BZ597629; GENBANK-BZ597630; GENBANK-BZ597631; GENBANK-BZ597632; GENBANK-BZ597633; GENBANK-BZ597634; GENBANK-BZ597635; GENBANK-BZ597636; GENBANK-BZ597637; GENBANK-BZ597638; GENBANK-BZ597639; GENBANK-BZ597640; GENBANK-BZ597641; GENBANK-BZ597642; GENBANK-BZ597643; GENBANK-BZ597644; GENBANK-BZ597645; GENBANK-BZ597646; GENBANK-BZ597647; GENBANK-BZ597648; GENBANK-BZ597649; GENBANK-BZ597650; GENBANK-BZ597651; GENBANK-BZ597652; GENBANK-BZ597653; GENBANK-BZ597654; GENBANK-BZ597655; GENBANK-BZ597656; GENBANK-BZ597657; GENBANK-BZ597658; GENBANK-BZ597659; GENBANK-BZ597660; GENBANK-BZ597661; GENBANK-BZ597662; GENBANK-BZ597663; GENBANK-BZ597664; GENBANK-BZ597665; GENBANK-BZ597666; GENBANK-BZ597667; GENBANK-BZ597668; GENBANK-BZ597669; GENBANK-BZ597670; GENBANK-BZ597671; GENBANK-BZ597672; GENBANK-BZ597673; GENBANK-BZ597674; GENBANK-BZ597675; GENBANK-BZ597676; GENBANK-BZ597677; GENBANK-BZ597678; GENBANK-BZ597679; GENBANK-BZ597680; GENBANK-BZ597681; GENBANK-BZ597682; GENBANK-BZ597683; GENBANK-BZ597684; GENBANK-BZ597685; GENBANK-BZ597686; GENBANK-BZ597687; GENBANK-BZ597688; GENBANK-BZ597689; GENBANK-BZ597690; GENBANK-BZ597691; GENBANK-BZ597692; GENBANK-BZ597693; GENBANK-BZ597694; GENBANK-BZ597695; GENBANK-BZ597696; GENBANK-BZ597697; GENBANK-BZ597698; GENBANK-BZ597699; GENBANK-BZ597700; GENBANK-BZ597701; GENBANK-BZ597702; GENBANK-BZ597703; GENBANK-BZ597704; GENBANK-BZ597705; GENBANK-BZ597706; GENBANK-BZ597707; GENBANK-BZ597708; GENBANK-BZ597709; GENBANK-BZ597710; GENBANK-BZ597711; GENBANK-BZ597712; GENBANK-BZ597713; GENBANK-BZ597714; GENBANK-BZ597715; GENBANK-BZ597716; GENBANK-BZ597717; GENBANK-BZ597718; GENBANK-BZ597719; GENBANK-BZ597720; GENBANK-BZ597721;

GENBANK-BZ598478; GENBANK-BZ598479; GENBANK-BZ598480; GENBANK-BZ598481;  
GENBANK-BZ598482; GENBANK-BZ598483; GENBANK-BZ598484; GENBANK-BZ598485;  
GENBANK-BZ598486; GENBANK-BZ598487; GENBANK-BZ598488; GENBANK-BZ598489;  
GENBANK-BZ598490; GENBANK-BZ598491; GENBANK-BZ598492; GENBANK-BZ598493;  
GENBANK-BZ598494; GENBANK-BZ598495; GENBANK-BZ598496; GENBANK-BZ598497;  
GENBANK-BZ598498; GENBANK-BZ598499; GENBANK-BZ598500; GENBANK-BZ598501;  
GENBANK-BZ598502; GENBANK-BZ598503; GENBANK-BZ598504; GENBANK-BZ598505;  
GENBANK-BZ598506; GENBANK-BZ598507; GENBANK-BZ598508; GENBANK-BZ598509;  
GENBANK-BZ598510; GENBANK-BZ598511; GENBANK-BZ598512; GENBANK-BZ598513;  
GENBANK-BZ598514; GENBANK-BZ598515; GENBANK-BZ598516; GENBANK-BZ598517;  
GENBANK-BZ598518; GENBANK-BZ598519; GENBANK-BZ598520; GENBANK-BZ598521;  
GENBANK-BZ598522; GENBANK-BZ598523; GENBANK-BZ598524; GENBANK-BZ598525;  
GENBANK-BZ598526; GENBANK-BZ598527; GENBANK-BZ598528; GENBANK-BZ598529;  
GENBANK-BZ598530; GENBANK-BZ598531; GENBANK-BZ598532; GENBANK-BZ598533;  
GENBANK-BZ598534; GENBANK-BZ598535; GENBANK-BZ598536; GENBANK-BZ598537;  
GENBANK-BZ598538; GENBANK-BZ598539; GENBANK-BZ598540; GENBANK-BZ598541;  
GENBANK-BZ598542; GENBANK-BZ598543; GENBANK-BZ598544; GENBANK-BZ598545;  
GENBANK-BZ598546; GENBANK-BZ598547; GENBANK-BZ598548; GENBANK-BZ598549;  
GENBANK-BZ598550; GENBANK-BZ598551; GENBANK-BZ598552; GENBANK-BZ598553;  
GENBANK-BZ598554; GENBANK-BZ598555; GENBANK-BZ598556; GENBANK-BZ598557;  
GENBANK-BZ598558; GENBANK-BZ598559; GENBANK-BZ598560; GENBANK-BZ598561;  
GENBANK-BZ598562; GENBANK-BZ598563; GENBANK-BZ598564; GENBANK-BZ598565;  
GENBANK-BZ598566; GENBANK-BZ598567; GENBANK-BZ598568; GENBANK-BZ598569;  
GENBANK-BZ598570; GENBANK-BZ598571; GENBANK-BZ598572; GENBANK-BZ598573;  
GENBANK-BZ598574; GENBANK-BZ598575; GENBANK-BZ598576; GENBANK-BZ598577;  
GENBANK-BZ598578; GENBANK-BZ598579; GENBANK-BZ598580; GENBANK-BZ598581;  
GENBANK-BZ598582; GENBANK-BZ598583; GENBANK-BZ598584; GENBANK-BZ598585;  
GENBANK-BZ598586; GENBANK-BZ598587; GENBANK-BZ598588; GENBANK-BZ598589;  
GENBANK-BZ598590; GENBANK-BZ598591; GENBANK-BZ598592; GENBANK-BZ598593;  
GENBANK-BZ598594; GENBANK-BZ598595; GENBANK-BZ598596; GENBANK-BZ598597;  
GENBANK-BZ598598; GENBANK-BZ598599; GENBANK-BZ598600; GENBANK-BZ598601;  
GENBANK-BZ598602; GENBANK-BZ598603; GENBANK-BZ598604; GENBANK-BZ598605;  
GENBANK-BZ598606; GENBANK-BZ598607; GENBANK-BZ598608; GENBANK-BZ598609;  
GENBANK-BZ598610; GENBANK-BZ598611; GENBANK-BZ598612; GENBANK-BZ598613

ED Entered STN: 20030626

Last Updated on STN: 20030709

AB **Genome** rearrangements are important in evolution, cancer, and other diseases. Precise mapping of the rearrangements is essential for identification of the involved genes, and many techniques have been developed for this purpose. We show here that **end-sequence profiling (ESP)** is particularly well suited to this purpose. **ESP** is accomplished by constructing a bacterial artificial **chromosome (BAC)** library from a test **genome**, measuring **BAC end sequences**, and mapping **end-sequence** pairs onto the normal **genome** sequence. Plots of **BAC end-sequences** density identify copy number abnormalities at high resolution. **BACs** spanning structural aberrations have end pairs that map abnormally far apart on the normal **genome** sequence. These pairs can then be sequenced to determine the involved genes and breakpoint sequences. **ESP** analysis of the breast cancer cell line MCF-7 demonstrated its utility for analysis of complex **genomes**. **End sequencing** of approximately 8,000 clones (0.37-fold haploid **genome clonal** coverage) produced a comprehensive **genome** copy number map of the MCF-7 **genome** at better than 300-kb resolution and identified 381 **genome** breakpoints, a subset of which was verified by fluorescence in situ hybridization mapping and sequencing.

L64 ANSWER 2 OF 10 MEDLINE

AN 2001105556 MEDLINE

DN 20568493 PubMed ID: 11116098

TI Detection of deleted **genomic DNA** using a semiautomated



computational analysis of GeneChip data.

CM Comment in: Genome Res. 2000 Dec;10(12):1837-9  
 AU Salamon H; Kato-Maeda M; Small P M; Drenkow J; Gingeras T R  
 CS Division of Infectious Diseases and Geographic Medicine, Department of  
 Medicine, Stanford University, Stanford, California 94305, USA..  
 Hugh.Salamon@Berlex.com  
 SO GENOME RESEARCH, (2000 Dec) 10 (12) 2044-54.  
 Journal code: 9518021. ISSN: 1088-9051.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200102  
 ED Entered STN: 20010322  
 Last Updated on STN: 20010322  
 Entered Medline: 20010208  
 AB **Genomic** diversity within and between populations is caused by  
 single nucleotide mutations, changes in repetitive **DNA** systems,  
 recombination mechanisms, and insertion and deletion events. The  
 contribution of these sources to diversity, whether purely genetic or of  
 phenotypic consequence, can only be investigated if we have the means to  
 quantitate and characterize diversity in many samples. With the advent of  
 complete sequence characterization of representative **genomes** of  
 different species, the possibility of developing protocols to screen for  
 genetic polymorphism across entire **genomes** is actively being  
 pursued. The large numbers of measurements such approaches yield demand  
 that we pay careful attention to the numerical analysis of data. In this  
 paper we present a novel application of an Affymetrix GeneChip to perform  
**genome**-wide screens for deletion polymorphism. A high-density  
 oligonucleotide array formatted for mRNA expression and targeted at a  
 fully sequenced 4.4-million-base pair Mycobacterium tuberculosis standard  
 strain **genome** was adapted to compare **genomic**  
**DNA**. Hybridization intensities to 111,000 probe pairs (perfect  
 complement and mismatch complement) were measured for **genomic**  
**DNA** from a clinical strain and from a vaccine organism. Because  
 individual probe-pair hybridization intensities exhibit limited  
 sensitivity/specificity characteristics to detect deletions,  
 data-analytical methodology to exploit measurements from multiple probes  
 in tandem locations across the **genome** was developed. The TSTEP  
 (Tandem Set **Terminal** Extreme Probability) algorithm designed  
 specifically to analyze the tandem hybridization measurements data was  
 applied and shown to discover **genomic** deletions with high  
 sensitivity. The TSTEP algorithm provides a foundation for similar  
 efforts to characterize deletions in many hybridization measures in  
 similar-sized and larger **genomes**. Issues relating to the design  
 of **genome** content screening experiments and the implications of  
 these methods for studying population **genomics** and the evolution  
 of **genomes** are discussed.  
 CT Algorithms  
 \*Computational Biology: MT, methods  
 \*DNA, Bacterial: AN, analysis  
 \*DNA, Bacterial: GE, genetics  
 Genes, Bacterial: GE, genetics  
 Genome, Bacterial  
 Mycobacterium bovis: GE, genetics  
 Mycobacterium tuberculosis: GE, genetics  
 \*Oligonucleotide Array Sequence Analysis: MT, methods  
 \*Sequence Deletion: GE, genetics  
 CN 0 (DNA, Bacterial)  
 L64 ANSWER 3 OF 10 MEDLINE  
 AN 2000433824 MEDLINE  
 DN 20277483 PubMed ID: 10819332

CS Laboratory for Computer Science, Massachusetts Institute of Technology,  
Cambridge, Massachusetts 02139 USA.

SO GENOME RESEARCH, (1999 Dec) 9 (12) 1163-74.  
Journal code: 9518021. ISSN: 1088-9051.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200001

ED Entered STN: 20000204  
Last Updated on STN: 20000204  
Entered Medline: 20000127

AB One approach to sequencing a large **genome** is (1) to sequence a collection of nonoverlapping "seeds" chosen from a **genomic** library of large-insert **clones** [such as bacterial artificial **chromosomes** (BACs)] and then (2) to take successive "walking" steps by selecting and sequencing minimally overlapping **clones**, using information such as **clone-end sequences** to identify the overlaps. In this paper we analyze the strategic issues involved in using this approach. We derive formulas showing how two key factors, the initial density of seed **clones** and the depth of the **genomic** library used for walking, affect the cost and time of a sequencing project-that is, the amount of redundant sequencing and the number of steps to cover the vast majority of the **genome**. We also discuss a variant strategy in which a second **genomic** library with **clones** having a somewhat smaller insert size is used to close gaps. This approach can dramatically decrease the amount of redundant sequencing, without affecting the rate at which the **genome** is covered.

CT Check Tags: Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.  
\*Chromosome Walking: MT, methods  
Chromosomes, Bacterial  
Cloning, Molecular: MT, methods  
\*Genome  
Models, Genetic  
\*Sequence Analysis, DNA: MT, methods

L64 ANSWER 6 OF 10 MEDLINE

AN 1999157099 MEDLINE

DN 99157099 PubMed ID: 10037818

TI High throughput direct **end sequencing** of BAC **clones**.

AU Kelley J M; Field C E; Craven M B; Bocskai D; Kim U J; Rounsley S D; Adams M D

CS The Institute for Genomic Research, Rockville, MD 20850, USA and Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.

SO NUCLEIC ACIDS RESEARCH, (1999 Mar 15) 27 (6) 1539-46.  
Journal code: 0411011. ISSN: 0305-1048.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199904

ED Entered STN: 19990511  
Last Updated on STN: 19990511  
Entered Medline: 19990427

AB Libraries constructed in bacterial artificial **chromosome** (BAC) vectors have become the choice for **clone** sets in high throughput **genomic** sequencing projects primarily because of their high stability. BAC libraries have been proposed as a source for minimally over-lapping **clones** for sequencing large **genomic** regions, and the use of BAC **end sequences** (i.e. sequences adjoining the insert sites) has been proposed as a primary means

for selecting minimally overlapping **clones** for sequencing large **genomic** regions. For this strategy to be effective, high throughput methods for BAC **end sequencing** of all the **clones** in deep coverage BAC libraries needed to be developed. Here we describe a low cost, efficient, 96 well procedure for BAC **end sequencing**. These methods allow us to generate BAC **end sequences** from human and Arabidopsis libraries with an average read length of >450 bases and with a single pass sequencing average accuracy of >98%. Application of BAC **end sequences** in **genomic** sequencing is discussed.

CT Check Tags: Human; Support, U.S. Gov't, Non-P.H.S.

Arabidopsis: GE, genetics

Base Sequence

\*Chromosomes, Bacterial

Cloning, Molecular: MT, methods

\*F Factor

Gene Library

Molecular Sequence Data

Selection (Genetics)

Sequence Analysis, DNA: EC, economics

\*Sequence Analysis, DNA: MT, methods

CN 0 (F Factor)

L64 ANSWER 7 OF 10 MEDLINE

AN 97264341 MEDLINE

DN 97264341 PubMed ID: 9110174

TI Large-scale concatenation cDNA sequencing.

AU Yu W; Andersson B; Worley K C; Muzny D M; Ding Y; Liu W; Ricafrente J Y;

Wentland M A; Lennon G; Gibbs R A

NC 1F32 HG00169-01 (NHGRI)

P30 HG00210-05 (NHGRI)

R01 HG00823 (NHGRI)

SO GENOME RESEARCH, (1997 Apr) 7 (4) 353-8.

Journal code: 9518021. ISSN: 1088-9051.

CY United States

DT Letter

LA English

FS Priority Journals

OS GENBANK-AF007128; GENBANK-AF007129; GENBANK-AF007130; GENBANK-AF007131;  
GENBANK-AF007132; GENBANK-AF007133; GENBANK-AF007134; GENBANK-AF007135;  
GENBANK-AF007136; GENBANK-AF007137; GENBANK-AF007138; GENBANK-AF007139;  
GENBANK-AF007140; GENBANK-AF007141; GENBANK-AF007142; GENBANK-AF007143;  
GENBANK-AF007144; GENBANK-AF007145; GENBANK-AF007146; GENBANK-AF007147;  
GENBANK-AF007148; GENBANK-AF007149; GENBANK-AF007150; GENBANK-AF007151;  
GENBANK-AF007152; GENBANK-AF007153; GENBANK-AF007154

EM 199706

ED Entered STN: 19970630

Last Updated on STN: 20000303

Entered Medline: 19970617

AB A total of 100 kb of **DNA** derived from 69 individual human brain cDNA **clones** of 0.7-2.0 kb were sequenced by concatenated cDNA sequencing (CCS), whereby multiple individual **DNA** fragments are sequenced simultaneously in a single shotgun library. The method yielded accurate sequences and a similar efficiency compared with other shotgun libraries constructed from single **DNA** fragments (> 20 kb). Computer analyses were carried out on 65 cDNA **clone** sequences and their corresponding **end sequences** to examine both nucleic acid and amino acid sequence similarities in the databases. Thirty-seven **clones** revealed no **DNA** database matches, 12 **clones** generated exact matches (> or = 98% identity), and 16 **clones** generated nonexact matches (57%-97% identity) to either known human or other species genes. Of those 28 matched **clones**, 8 had corresponding **end sequences** that failed to

identify similarities. In a protein similarity search, 27 **clone** sequences displayed significant matches, whereas only 20 of the **end sequences** had matches to known protein sequences. Our data indicate that full-length cDNA insert sequences provide significantly more nucleic acid and protein sequence similarity matches than expressed sequence tags (ESTs) for database searching.

CT Check Tags: Human; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.

**DNA Transposable Elements**

**DNA, Complementary: CH, chemistry**

**\*DNA, Complementary: GE, genetics**

Databases, Factual

Gene Library

Molecular Sequence Data

Proteins: CH, chemistry

\*Proteins: GE, genetics

**\*Sequence Alignment: MT, methods**

**\*Sequence Analysis, DNA: MT, methods**

Sequence Homology, Amino Acid

Sequence Homology, Nucleic Acid

Software

CN 0 (**DNA Transposable Elements**); 0 (**DNA, Complementary**);

0 (**Proteins**)

L64 ANSWER 8 OF 10 MEDLINE

AN 97092874 MEDLINE

DN 97092874 PubMed ID: 8938436

TI **End sequence** determination from large insert **clones** using energy transfer fluorescent primers.

AU Marra M; Weinstock L A; Mardis E R

CS Genome Sequencing Center, St. Louis, Missouri 63108, USA.

SO GENOME RESEARCH, (1996 Nov) 6 (11) 1118-22.

Journal code: 9518021. ISSN: 1088-9051.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199702

ED Entered STN: 19970306

Last Updated on STN: 19980206

Entered Medline: 19970227

AB **Genome** mapping strategies depend heavily on confirmatory data of several types to establish overlaps between contiguous stretches of **cloned DNA** derived from **genomic** regions. One type of ancillary data that can contribute to establishing these overlaps is **DNA** sequence data derived from the ends of large (> 30 kb) inserts in **genomic clones**. This type of data can be difficult to obtain routinely, because large **clones** are often unstable and microgram quantities of highly purified **DNA** are required in each sequencing reaction to obtain sufficient signal for accurate base calling and maximum read length. Recently, we have been experimenting with methods to consistently obtain up to 800 bases of high-quality sequence data from the ends of large insert **clones** using ThermoSequenase **DNA** polymerase and Energy Transfer fluorescent primers. Our experimental approach and results, described in this paper, indicate that routinely obtaining high-quality sequence data from the ends of large insert **genomic clones** is feasible. Such data can contribute to the assessment of common regions between large insert **clones**, to the establishment of conservation of syntenry between closely related species, and to the detection of additional contiguous **clones**.

CT **\*Chromosome Mapping: MT, methods**

Cloning, Molecular

DNA: AN, analysis

DNA Primers: CH, chemistry

DNA Primers: GE, genetics

DNA-Directed DNA Polymerase: ME, metabolism

Fluorescence

\*Sequence Analysis: MT, methods

RN 9007-49-2 (DNA)

CN 0 (DNA Primers); EC 2.7.7.7 (DNA-Directed DNA Polymerase)

L64 ANSWER 9 OF 10 MEDLINE

AN 96121589 MEDLINE

DN 96121589 PubMed ID: 8595414

TI Quantitative DNA fiber mapping.

AU Weier H U; Wang M; Mullikin J C; Zhu Y; Cheng J F; Greulich K M; Bensimon A; Gray J W

CS Center for Molecular Cytogenetics, University of California, Lawrence Berkeley Laboratory, Berkeley 94720, USA.

NC CA 58207 (NCI)

SO HUMAN MOLECULAR GENETICS, (1995 Oct) 4 (10) 1903-10.

Journal code: 9208958. ISSN: 0964-6906.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

OS GENBANK-U09128; GENBANK-X54156; GENBANK-X65279

EM 199604

ED Entered STN: 19960424

Last Updated on STN: 19960424

Entered Medline: 19960418

AB The assembly of sequence ready, high-resolution physical maps and construction of minimally overlapping contigs for the human as well as model **genomes** requires accurate determination of the extent of overlap between adjacent **clones** as well as their relative orientation. This is presently done by procedures such as **clone** fingerprinting, Southern blot analysis or **clone end sequencing**. We present a complementary analytical technique to map directly **cloned DNA** sequences on to individual stretched **DNA** molecules. This approach uses the hydrodynamic force of a receding meniscus to prepare straight high molecular weight **DNA** molecules that provide a linear template of approximately 2.3 kb/microns on to which the **cloned** probes can be mapped by in situ hybridization. This technique has numerous advantages such as a very high density of mapping templates, reproducible stretching of the mapping template providing a linear **genomic** scale, determination of **clone** orientation and direct visualization of **DNA** repeats. The utility and accuracy of quantitative **DNA** fiber mapping are illustrated through three examples: (i) mapping of lambda **DNA** restriction fragments along linearized approximately 49 kb long lambda phage **DNA** molecules with approximately 1 kb precision; (ii) localization of the overlap between a cosmid and a colinear P1 **clone**; and (iii) mapping of P1 **clones** along an approximately 490 kb yeast artificial **chromosome** (YAC) with approximately 5 kb precision and estimation of the approximately 25 kb gap between them.

CT Check Tags: Human; Support, U.S. Gov't, Non-P.H.S.; Support, U.S. Gov't, P.H.S.

Bacteriophage lambda: GE, genetics

\*Chromosome Mapping

Chromosomes, Artificial, Yeast

Cloning, Molecular

Cosmids

DNA: CH, chemistry

DNA: GE, genetics  
 DNA Probes  
 DNA, Viral: CH, chemistry  
 DNA, Viral: GE, genetics  
 \*Genome  
 \*Genome, Human  
 In Situ Hybridization, Fluorescence  
 Molecular Sequence Data  
 Restriction Mapping

RN 9007-49-2 (DNA)  
 CN 0 (Chromosomes, Artificial, Yeast); 0 (Cosmids); 0 (DNA Probes); 0 (DNA, Viral)

L64 ANSWER 10 OF 10 MEDLINE

AN 95324927 MEDLINE

DN 95324927 PubMed ID: 7601461

TI Pairwise end sequencing: a unified approach to genomic mapping and sequencing.

AU Roach J C; Boysen C; Wang K; Hood L

CS Department of Molecular Biotechnology, University of Washington, Seattle 98195, USA.

SO GENOMICS, (1995 Mar 20) 26 (2) 345-53.

Journal code: 8800135. ISSN: 0888-7543.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199508

ED Entered STN: 19950822

Last Updated on STN: 19950822

Entered Medline: 19950808

AB Strategies for large-scale genomic DNA sequencing currently require physical mapping, followed by detailed mapping, and finally sequencing. The level of mapping detail determines the amount of effort, or sequence redundancy, required to finish a project. Current strategies attempt to find a balance between mapping and sequencing efforts. One such approach is to employ strategies that use sequence data to build physical maps. Such maps alleviate the need for prior mapping and reduce the final required sequence redundancy. To this end, the utility of correlating pairs of sequence data derived from both ends of subcloned templates is well recognized. However, optimal strategies employing such pairwise data have not been established. In the present work, we simulate and analyze the parameters of pairwise sequencing projects including template length, sequence read length, and total sequence redundancy. One pairwise strategy based on sequencing both ends of plasmid subclones is recommended and illustrated with raw data simulations. We find that pairwise strategies are effective with both small (cosmid) and large (megaYAC) targets and produce ordered sequence data with a high level of mapping completeness. They are ideal for finescale mapping and gene finding and as initial steps for either a high- or a low-redundancy sequencing effort. Such strategies are highly automatable.

CT Check Tags: Support, Non-U.S. Gov't  
 Base Composition

\*Chromosome Mapping: MT, methods

Computer Simulation

Cosmids: GE, genetics

\*Genome

\*Sequence Analysis, DNA: MT, methods

Templates, Genetic

CN 0 (Cosmids)

*not for  
 comparison.  
 But clearly  
 delineated  
 advantages  
 may include  
 in primary  
 seq.*

=> fil medline

FILE 'MEDLINE' ENTERED AT 14:40:14 ON 16 JUL 2003

FILE LAST UPDATED: 15 JUL 2003 (20030715/UP). FILE COVERS 1958 TO DATE.

On April 13, 2003, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/changes2003.html> for a description on changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot

L66 ANSWER 1 OF 3 MEDLINE  
AN 1999157099 MEDLINE  
DN 99157099 PubMed ID: 10037818  
TI High throughput direct **end sequencing** of BAC clones.  
AU Kelley J M; Field C E; Craven M B; Bocskai D; Kim U J; Rounsley S D; Adams M D  
CS The Institute for Genomic Research, Rockville, MD 20850, USA and Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.  
SO NUCLEIC ACIDS RESEARCH, (1999 Mar 15) 27 (6) 1539-46.  
Journal code: 0411011. ISSN: 0305-1048.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199904  
ED Entered STN: 19990511  
Last Updated on STN: 19990511  
Entered Medline: 19990427  
AB Libraries constructed in bacterial artificial chromosome (BAC) vectors have become the choice for clone sets in high throughput genomic sequencing projects primarily because of their high stability. BAC libraries have been proposed as a source for minimally over-lapping clones for sequencing large genomic regions, and the use of BAC **end sequences** (i.e. sequences adjoining the insert sites) has been proposed as a primary means for selecting minimally overlapping clones for sequencing large genomic regions. For this strategy to be effective, high throughput methods for BAC **end sequencing** of all the clones in deep coverage BAC libraries needed to be developed. Here we describe a low cost, efficient, 96 well procedure for BAC **end sequencing**. These methods allow us to generate BAC **end sequences** from human and Arabidopsis libraries with an average read length of >450 bases and with a single pass sequencing average accuracy of >98%. Application of BAC **end sequences** in genomic sequen-cing is discussed. *use it*  
CT Check Tags: Human; Support, U.S. Gov't, Non-P.H.S. *see it*  
Arabidopsis: GE, genetics  
Base Sequence  
\*Chromosomes, Bacterial  
Cloning, Molecular: MT, methods  
\*F Factor  
Gene Library  
Molecular Sequence Data  
Selection (Genetics)  
Sequence Analysis, DNA: EC, economics  
\*Sequence Analysis, DNA: MT, methods  
CN 0 (F Factor)

. ISSN: 1046-7386.

DT **Conference**  
 LA English  
 CC **General Biology - Symposia, Transactions and Proceedings of  
 Conferences, Congresses, Review Annuals \*00520**  
 Biochemical Studies - General \*10060  
     **Biochemical Studies - Nucleic Acids, Purines and Pyrimidines  
     \*10062**  
 IT Major Concepts  
     Biochemistry and Molecular Biophysics; Methods and Techniques  
 IT Chemicals & Biochemicals  
     DNA: copy number, microarray; RNA: expression  
 IT Miscellaneous Descriptors  
     **Meeting Abstract**

L92 ANSWER 6 OF 9 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
 AN 2002:142903 BIOSIS  
 DN PREV200200142903  
 TI Response to neoadjuvant therapy for breast cancer by magnetic resonance  
 imaging type, estrogen receptor status, grade, and comparative genomic  
 hybridization.  
 AU Esserman, L. J. (1); Sudilovsky, D. (1); Kuo, W.-I. (1); Gray, J.  
 (1); Hylton, N. (1)  
 CS (1) Breast Care Center, University of California, San Francisco, San  
 Francisco, CA USA  
 SO Breast Cancer Research and Treatment, (October, 2001) Vol. 69, No. 3, pp.  
 245. <http://www.kluweronline.com/issn/0167-6806>. print.  
 Meeting Info.: **24th Annual San Antonio Breast Cancer Symposium**  
 San Antonio, Texas, USA December 10-13, 2001  
 ISSN: 0167-6806.

DT **Conference**  
 LA English  
 CC **General Biology - Symposia, Transactions and Proceedings of  
 Conferences, Congresses, Review Annuals \*00520**  
 Radiation - Radiation and Isotope Techniques \*06504  
 Biochemical Studies - General \*10060  
     **Biochemical Studies - Nucleic Acids, Purines and Pyrimidines  
     \*10062**  
 Pathology, General and Miscellaneous - Diagnostic \*12504  
 Pathology, General and Miscellaneous - Therapy \*12512  
 Reproductive System - Physiology and Biochemistry \*16504  
 Reproductive System - Pathology \*16506  
 Pharmacology - General \*22002  
 Pharmacology - Clinical Pharmacology \*22005  
 Neoplasms and Neoplastic Agents - Diagnostic Methods \*24001  
 Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic  
 Effects \*24004  
 Neoplasms and Neoplastic Agents - Therapeutic Agents; Therapy \*24008

BC Hominidae 86215  
 IT Major Concepts  
     Gynecology (Human Medicine, Medical Sciences); Oncology (Human  
     Medicine, Medical Sciences); Pharmacology; Radiology (Medical Sciences)  
 IT Parts, Structures, & Systems of Organisms  
     breast: reproductive system  
 IT Diseases  
     locally advanced breast cancer: neoplastic disease, reproductive system  
     disease/female, therapy  
 IT Chemicals & Biochemicals  
     Her2 Ab [Her2 antibody]; adriamycin: antineoplastic - drug; cytoxan:  
     antineoplastic - drug  
 IT Methods & Equipment  
     comparative genomic hybridization: analytical method; magnetic  
     resonance imaging: Imaging Techniques, diagnostic method; neoadjuvant



- therapy: efficacy, therapeutic method
- IT Miscellaneous Descriptors  
estrogen receptor status; treatment response; tumor diameter; tumor grade; **Meeting Abstract; Meeting Poster**
- ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
- ORGN Organism Name  
human (Hominidae): female, patient
- ORGN Organism Superterms  
Animals; Chordates; Humans; Mammals; Primates; Vertebrates
- RN 25316-40-9 (ADRIAMYCIN)  
50-18-0 (CYTOXAN)
- L92 ANSWER 7 OF 9 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN **1996:555396** BIOSIS  
DN **PREV199699277752**  
TI Comparative genomic hybridization to arrayed DNA targets (CGHa) for high resolution analysis of DNA sequence copy number changes.  
AU Pinkel, D. (1); Segraves, R. (1); Sudar, D.; Van Vliet, L.; Zhai, Y. (1); **Gray, J. W. (1); Albertson, D. G.**  
CS (1) Univ. Calif., San Francisco, CA USA  
SO American Journal of Human Genetics, (1996) Vol. 59, No. 4 SUPPL., pp. A78.  
Meeting Info.: **46th Annual Meeting of the American Society of Human Genetics** San Francisco, California, USA October 29-November 2, 1996  
ISSN: 0002-9297.  
DT **Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**  
Microscopy Techniques - Cytology and Cytochemistry \*01054  
Cytology and Cytochemistry - General \*02502  
Genetics and Cytogenetics - General \*03502  
**Biochemical Methods - Nucleic Acids, Purines and Pyrimidines \*10052**  
Biophysics - General Biophysical Techniques \*10504  
Biophysics - Molecular Properties and Macromolecules \*10506  
Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic Effects \*24004
- IT Major Concepts  
Biochemistry and Molecular Biophysics; Cell Biology; Genetics; Methods and Techniques; Tumor Biology
- IT Miscellaneous Descriptors  
ANALYTICAL METHOD; CANCER GENES; CANCER GENETICS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA; GENETIC METHOD; **MEETING ABSTRACT**  
; **MEETING POSTER**; METHODOLOGY; MOLECULAR GENETICS;  
TUMOR BIOLOGY
- L92 ANSWER 8 OF 9 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN **1995:142045** BIOSIS  
DN **PREV199598156345**  
TI DNA copy number alterations in primary cutaneous malignant melanoma using comparative genomic hybridization.  
AU White, W. L. (1); Thompson, C. T.; Halaban, R.; Khavari, R.; **Gray, J. W.**; Pinkel, D.  
CS (1) Bowman Gray Sch. Med., Winston-Salem, NC USA  
SO Modern Pathology, (1995) Vol. 8, No. 1, pp. 52A.  
Meeting Info.: **Annual Meeting of the United States and Canadian Academy of Pathology** Toronto, Ontario, Canada March 11-17, 1995  
ISSN: 0893-3952.  
DT **Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of**

**Conferences, Congresses, Review Annuals 00520**

Cytology and Cytochemistry - Human \*02508

Clinical Biochemistry; General Methods and Applications \*10006

**Biochemical Studies - Nucleic Acids, Purines and Pyrimidines 10062**

Pathology, General and Miscellaneous - Diagnostic \*12504

Metabolism - Nucleic Acids, Purines and Pyrimidines \*13014

Integumentary System - Pathology \*18506

Neoplasms and Neoplastic Agents - Diagnostic Methods \*24001

Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic Effects \*24004

Neoplasms and Neoplastic Agents - Biochemistry \*24006

BC Hominidae \*86215

IT Major Concepts

Cell Biology; Clinical Chemistry (Allied Medical Sciences); Dermatology (Human Medicine, Medical Sciences); Metabolism; Oncology (Human Medicine, Medical Sciences); Pathology

IT Miscellaneous Descriptors

CHROMOSOMAL ABERRATION; DIAGNOSTIC METHOD; **MEETING****ABSTRACT; TUMOR PROGRESSION**

ORGN Super Taxa

Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name

human (Hominidae)

ORGN Organism Superterms

animals; chordates; humans; mammals; primates; vertebrates

L92 ANSWER 9 OF 9 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 1994:151247 BIOSIS

DN PREV199497164247

TI Use of comparative genomic hybridization to study genomic instability in neoplastic cells.

AU Roelofs, Helene; Lockett, Steve; Herman, Brian; Gray, Joe W.; Tlsty, Thea D.

CS Lineberger Comprehensive Cancer Center, University North Carolina, Chapel Hill, NC USA

SO Journal of Cellular Biochemistry Supplement, (1994) Vol. 0, No. 18 PART A, pp. 211.

Meeting Info.: **Keystone Symposium on Molecular Biology of Human****Genetic Disease** Copper Mountain, Colorado, USA January 15-22, 1994

ISSN: 0733-1959.

DT **Conference**

LA English

CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**

Cytology and Cytochemistry - Animal 02506

Genetics and Cytogenetics - Animal \*03506

**Biochemical Studies - Nucleic Acids, Purines and Pyrimidines 10062**

Replication, Transcription, Translation 10300

Neoplasms and Neoplastic Agents - Carcinogens and Carcinogenesis \*24007

IT Major Concepts

Genetics; Tumor Biology

IT Miscellaneous Descriptors

ANEUPLOIDY; CARCINOGENESIS; **MEETING ABSTRACT**

=&gt; d all tot

L98 ANSWER 1 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 2003:241548 BIOSIS

DN PREV200300241548

TI High resolution array **comparative genomic**

**hybridization** using archived prostate tissue to identify biomarkers of progression.

AU Paris, Pamela L. (1); Albertson, Donna (1); Andaya, Armann (1); Carroll, Peter (1); Fridlyand, Jane (1); Jain, Ajay (1); Kowbel, David (1); Pinkel, Dan (1); Watson, Vivienne (1); van Dekken, Herman; **Collins, Colin** (1)

CS (1) San Francisco, CA, USA USA

SO Journal of Urology, (April 2003, 2003) Vol. 169, No. 4 Supplement, pp. 435-436. print.

Meeting Info.: **98th Annual Meeting of the American Urological Association (AUA)** Chicago, IL, USA April 26-May 01, 2003 American Urological Association  
. ISSN: 0022-5347.

DT **Conference**

LA English

CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals \*00520**

Genetics and Cytogenetics - General \*03502

Genetics and Cytogenetics - Human \*03508

Enzymes - General and Comparative Studies; Coenzymes \*10802

Pathology, General and Miscellaneous - General \*12502

Pathology, General and Miscellaneous - Diagnostic \*12504

Urinary System and External Secretions - Pathology \*15506

Reproductive System - Physiology and Biochemistry \*16504

Reproductive System - Pathology \*16506

Neoplasms and Neoplastic Agents - Diagnostic Methods \*24001

Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic Effects \*24004

Neoplasms and Neoplastic Agents - Carcinogens and Carcinogenesis \*24007

BC Hominidae 86215

IT Major Concepts

Molecular Genetics (Biochemistry and Molecular Biophysics); Oncology (Human Medicine, Medical Sciences); Urology (Human Medicine, Medical Sciences)

IT Parts, Structures, & Systems of Organisms  
prostate: reproductive system

IT Diseases

prostate cancer: diagnosis, genetics, neoplastic disease, pathology, reproductive system disease/male, urologic disease

IT Chemicals & Biochemicals

prostate specific antigen [EC 3.4.21.77]

IT Alternate Indexing

Prostatic Neoplasms (MeSH)

IT Methods & Equipment

Gleason score: clinical techniques, diagnostic techniques; high resolution array **comparative genomic hybridization**: genetic techniques, laboratory techniques; microdissection: laboratory techniques

IT Miscellaneous Descriptors

carcinogenesis; clinical outcome; progression biomarkers;  
**Meeting Abstract**

ORGN Super Taxa

Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name

human (Hominidae): male, patient

ORGN Organism Superterms

Animals; Chordates; Humans; Mammals; Primates; Vertebrates

L98 ANSWER 2 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 2002:616018 BIOSIS

DN PREV200200616018

TI Correlating array CGH with gene expression and sensitivity to drugs in a panel of 60 human cancer cell lines.

AU Bussey, K. J. (1); Chin, K.; Reinhold, W. C. (1); Lababidi, S. (1);  
Gwadry, F.; Scherf, U.; Ajay; Tonon, G.; Roschke, A.; Stover, K.; Kirsch,  
I.; Scudiero, D. A.; **Gray, J. W.**; Weinstein, J. N. (1)  
CS (1) Laboratory of Molecular Pharmacology, National Cancer Institute,  
Bethesda, MD USA  
SO American Journal of Human Genetics, (October, 2002) Vol. 71, No. 4  
Supplement, pp. 200. <http://www.journals.uchicago.edu/AJHG/home.html>.  
print.  
Meeting Info.: **52nd Annual Meeting of the American Society of Human  
Genetics** Baltimore, MD, USA October 15-19, 2002 American Society of  
Human Genetics  
. ISSN: 0002-9297.  
DT **Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals \*00520**  
Genetics and Cytogenetics - General \*03502  
Genetics and Cytogenetics - Human \*03508  
Enzymes - General and Comparative Studies; Coenzymes \*10802  
Pathology, General and Miscellaneous - Therapy \*12512  
Blood, Blood-Forming Organs and Body Fluids - Blood, Lymphatic and  
Reticuloendothelial Pathologies \*15006  
Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic  
Effects \*24004  
Neoplasms and Neoplastic Agents - Therapeutic Agents; Therapy \*24008  
Neoplasms and Neoplastic Agents - Blood and Reticuloendothelial Neoplasms  
\*24010  
BC Hominidae 86215  
IT Major Concepts  
Molecular Genetics (Biochemistry and Molecular Biophysics); Tumor  
Biology  
IT Diseases  
ALL [acute lymphoblastic leukemia]: blood and lymphatic disease,  
neoplastic disease; cancer: neoplastic disease  
IT Chemicals & Biochemicals  
L-asparaginase: antineoplastic - drug; asparagine synthetase; gene  
IT Alternate Indexing  
Neoplasms (MeSH)  
IT Methods & Equipment  
array CGH: analytical method  
IT Miscellaneous Descriptors  
DNA copy number; **Meeting Abstract**  
ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia  
ORGN Organism Name  
human (Hominidae)  
ORGN Organism Superterms  
Animals; Chordates; Humans; Mammals; Primates; Vertebrates  
RN 9015-68-3 (L-ASPARAGINASE)  
9023-69-2 (ASPARAGINE SYNTHETASE)  
L98 ANSWER 3 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN **2002:1365 BIOSIS**  
DN **PREV200200001365**  
TI Genetic profiling of non-small cell lung cancer using array-  
**Comparative Genomic hybridization.**  
AU Massion, Pierre P. (1); Kuo, Wen-Lin (1); Chin, Koei (1); Treseler,  
Patrick (1); Chen, Chira (1); Polikoff, Daniel (1); Pinkel, Daniel (1);  
Albertson, Donna (1); Jain, Ajay (1); Jablons, David (1); **Gray, Joe**  
**(1)**  
CS (1) UCSF, San Francisco, CA USA  
SO **Proceedings of the American Association for Cancer Research Annual  
Meeting**, (March, 2001) Vol. 42, pp. 745. print.

Meeting Info.: 92nd Annual Meeting of the American Association for  
Cancer Research New Orleans, LA, USA March 24-28, 2001  
ISSN: 0197-016X.

DT **Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals \*00520**  
Genetics and Cytogenetics - General \*03502  
Genetics and Cytogenetics - Human \*03508  
Respiratory System - Pathology \*16006  
Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic  
Effects \*24004  
BC Hominidae 86215  
IT Major Concepts  
Molecular Genetics (Biochemistry and Molecular Biophysics); Oncology  
(Human Medicine, Medical Sciences)  
IT Diseases  
non-small cell lung cancer: neoplastic disease, respiratory system  
disease  
IT Alternate Indexing  
Lung Neoplasms (MeSH); Carcinoma, Non-Small-Cell Lung (MeSH)  
IT Methods & Equipment  
array-**Comparative Genomic Hybridization:**  
detection method, genetic method  
IT Miscellaneous Descriptors  
cancer genetic profiling; cancer genetics; **Meeting  
Abstract**  
ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia  
ORGN Organism Name  
human (Hominidae): patient  
ORGN Organism Superterms  
Animals; Chordates; Humans; Mammals; Primates; Vertebrates  
  
L98 ANSWER 4 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 2002:1362 BIOSIS  
DN PREV200200001362  
TI Genome wide screening of gene copy number changes on the NCI 60 cell lines  
using array CGH.  
AU Chin, Koei (1); Kuo, Wen-Lin; Jain, Ajay; Albertson, Donna; Pinkel, Dan;  
Scherf, Uwe; Reinhold, William C.; Weinstein, John N.; **Gray, Joe  
W.**  
CS (1) National Cancer Institute, Bethesda, MD USA  
SO **Proceedings of the American Association for Cancer Research Annual  
Meeting, (March, 2001) Vol. 42, pp. 744. print.**  
Meeting Info.: 92nd Annual Meeting of the American Association for  
Cancer Research New Orleans, LA, USA March 24-28, 2001  
ISSN: 0197-016X.  
DT **Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals \*00520**  
Genetics and Cytogenetics - General \*03502  
Genetics and Cytogenetics - Animal \*03506  
Biochemical Studies - General \*10060  
Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic  
Effects \*24004  
BC Mammalia - Unspecified 85700  
IT Major Concepts  
Biochemistry and Molecular Biophysics; Genetics; Tumor Biology  
IT Methods & Equipment  
array **comparative genomic hybridization:**  
detection method, genetic method, screening method

IT Miscellaneous Descriptors  
gene copy number changes: genome wide screening; **Meeting Abstract**

CO National Cancer Institute

ORGN Super Taxa  
Mammalia: Vertebrata, Chordata, Animalia

ORGN Organism Name  
mammal (Mammalia): NCI 60 cell lines

ORGN Organism Superterms  
Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Vertebrates

L98 ANSWER 5 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN **2001:440426** BIOSIS

DN **PREV200100440426**

TI **Genomic profiling of ovarian cancer by array comparative genomic hybridization.**

AU Kuo, Wen-Lin (1); Polikoff, Daniel; Yamada, Kyosuke; Glenn, Pat; Zaloudek, Chuck; Smith-McCune, Karen; Mills, Gordon B.; Lu, Karen; Deavers, Mike; Shaw, Pat; **Collins, Colin**; Hamilton, Greg; Jain, Ajay; Brown, Nils; Albertson, Donna; Pinkel, Dan; **Gray, Joe W.**

CS (1) MD Anderson Cancer Center, Houston, TX USA

SO **Proceedings of the American Association for Cancer Research Annual Meeting**, (March, 2001) Vol. 42, pp. 429. print.  
Meeting Info.: **92nd Annual Meeting of the American Association for Cancer Research** New Orleans, LA, USA March 24-28, 2001  
ISSN: 0197-016X.

DT **Conference**

LA English

SL English

CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals \*00520**  
Genetics and Cytogenetics - General \*03502  
Reproductive System - Physiology and Biochemistry \*16504  
Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic Effects \*24004

IT Major Concepts  
Molecular Genetics (Biochemistry and Molecular Biophysics); Methods and Techniques; Reproductive System (Reproduction); Tumor Biology

IT Parts, Structures, & Systems of Organisms  
chromosome 16: locus q22-ter; chromosome 20: locus q13; chromosome 3: locus q22, locus q26; chromosome 8: q arm; ovary: reproductive system

IT Diseases  
gene abnormality: genetic disease; serous ovarian cancer: neoplastic disease, reproductive system disease/female

IT Methods & Equipment  
array **comparative genomic hybridization**:  
gene profiling method

IT Miscellaneous Descriptors  
**Meeting Abstract**

GEN AIB1 gene; BBC gene; BCL6 gene; CACNA1D gene; CMYC gene: amplification; CTSB gene; CYP24 gene; E-cadherin gene; EVI1 gene; FHIT gene; LBL gene; PIK3CA gene; PIK3CB gene; RHO gene; SPO11 gene; SST gene; TERC gene; THPO gene; THRB gene; VHL gene; ZNF217 gene; ZNF9 gene

L98 ANSWER 6 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN ~~2001:84904~~ BIOSIS

DN ~~PREV200100084904~~

TI ~~Changes in leg ulcers treated with compressive support.~~

AU ~~Roberts, G. H. (1); Hammad, L. (1); **Collins, C. S. (1)**; Creevy, J. (1); Shearman, S. P. (1); Mani, R. (1)~~

CS ~~(1) Southampton University Hospitals Trust, Tremona Road, Southampton, SO16 6YP UK~~

- SO Wound Repair and Regeneration, (September October, 2000) Vol. 8, No. 5, pp. A430. print.  
Meeting Info.: **Tenth Annual Meeting of the European Tissue Repair Society** Brussels, Belgium May 24-27, 2000  
ISSN: 1067-1927.
- DT **Conference**  
LA English  
SL English  
CC Integumentary System - Pathology \*18506  
**General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals \*00520**  
Pathology, General and Miscellaneous - Therapy \*12512  
Cardiovascular System - Heart Pathology \*14506  
Cardiovascular System - Blood Vessel Pathology \*14508
- BC Hominidae 86215  
IT Major Concepts  
Cardiovascular Medicine (Human Medicine, Medical Sciences); Dermatology (Human Medicine, Medical Sciences)
- IT Diseases  
venous leg ulcers: compressive support-induced changes, integumentary system disease, vascular disease
- IT Methods & Equipment  
Profore compressive bandage treatment: therapeutic method, venous leg ulcer changes
- IT Miscellaneous Descriptors  
**Meeting Abstract**
- ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
- ORGN Organism Name  
human (Hominidae): patient
- ORGN Organism Superterms  
Animals; Chordates; Humans; Mammals; Primates; Vertebrates
- L98 ANSWER 7 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 2000:275363 BIOSIS  
DN PREV200000275363  
TI Gene-based array CGH construction and tumor genome analysis.  
AU Polikoff, Daniel (1); Kuo, W.-L.; Massion, P.; Chin, K.; Collins, C.; Yue, P.; Myambo, K.; Riedell, L.; Wernick, M.; McCue, C.; Hamilton, G.; Glenn, P.  
CS (1) CA Institute of Technology, Pasadena, CA USA
- SO **Proceedings of the American Association for Cancer Research Annual Meeting**, (March, 2000) No. 41, pp. 726. print..  
Meeting Info.: **91st Annual Meeting of the American Association for Cancer Research**. San Francisco, California, USA April 01-05, 2000  
ISSN: 0197-016X.
- DT **Conference**  
LA English  
SL English  
CC Neoplasms and Neoplastic Agents - General \*24002  
Genetics and Cytogenetics - Human \*03508  
Biochemical Studies - General \*10060  
Biophysics - General Biophysical Studies \*10502  
Reproductive System - General; Methods \*16501  
Endocrine System - General \*17002  
Respiratory System - General; Methods \*16001  
**General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals \*00520**
- BC Hominidae 86215  
IT Major Concepts  
Molecular Genetics (Biochemistry and Molecular Biophysics); Tumor Biology
- IT Diseases

breast cancer: neoplastic disease, reproductive system disease/female;  
lung cancer: neoplastic disease, respiratory system disease; ovarian  
cancer: neoplastic disease, reproductive system disease/female

IT Alternate Indexing  
Breast Neoplasms (MeSH); Lung Neoplasms (MeSH); Ovarian Neoplasms (MeSH)

IT Methods & Equipment  
FISH [fluorescence in-situ **hybridization**]: genetic method;  
**comparative genomic hybridization** [CGH]:  
gene-based array, genetic method

IT Miscellaneous Descriptors  
**Meeting Abstract**

ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name  
human (Hominidae)

ORGN Organism Superterms  
Animals; Chordates; Humans; Mammals; Primates; Vertebrates

L98 ANSWER 8 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 2000:275352 BIOSIS  
DN PREV200000275352  
TI Oligonucleotide-array-based **comparative genomic hybridization**.

AU Baldocchi, Russ A. (1); Glynne, Richard J.; Kowbel, Dave; Tom, Ed;  
Segraves, Rick; Albertson, Donna; Pinkel, Dan; **Collins, Colin**;  
Mack, David H.; **Gray, Joe W.**

CS (1) Eos Biotech, Inc, S.San Francisco, CA USA

SO **Proceedings of the American Association for Cancer Research Annual Meeting**, (March, 2000) No. 41, pp. 724. print..  
Meeting Info.: **91st Annual Meeting of the American Association for Cancer Research**. San Francisco, California, USA April 01-05, 2000  
ISSN: 0197-016X.

DT **Conference**

LA English

SL English

CC Neoplasms and Neoplastic Agents - General \*24002  
Cytology and Cytochemistry - Human \*02508  
Genetics and Cytogenetics - Human \*03508  
Biochemical Studies - General \*10060  
Reproductive System - General; Methods \*16501  
Biophysics - General Biophysical Studies \*10502  
**General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals \*00520**

BC Hominidae 86215

IT Major Concepts  
Molecular Genetics (Biochemistry and Molecular Biophysics);  
Reproductive System (Reproduction); Tumor Biology

IT Diseases  
breast cancer: neoplastic disease, reproductive system disease/female

IT Alternate Indexing  
Breast Neoplasms (MeSH)

IT Methods & Equipment  
**comparative genomic hybridization**:  
genetic method, oligonucleotide array-based

IT Miscellaneous Descriptors  
**Meeting Abstract**

ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name  
MCF-7 cell line (Hominidae): human breast cancer cells

ORGN Organism Superterms  
Animals; Chordates; Humans; Mammals; Primates; Vertebrates



L98 ANSWER 9 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 2000:275314 BIOSIS  
DN PREV200000275314  
TI p53 inactivation under natural selection in brain tumor progression without significant chromosomal instability.  
AU Lu, Xiangdong (1); Magrane, G.; Gray, J.; Van Dyke, T.  
CS (1) Univ of CA at San Francisco, San Francisco, CA USA  
SO **Proceedings of the American Association for Cancer Research Annual Meeting**, (March, 2000) No. 41, pp. 717-718. print..  
Meeting Info.: **91st Annual Meeting of the American Association for Cancer Research**. San Francisco, California, USA April 01-05, 2000  
ISSN: 0197-016X.  
DT **Conference**  
LA English  
SL English  
CC Neoplasms and Neoplastic Agents - General \*24002  
Cytology and Cytochemistry - Animal \*02506  
Genetics and Cytogenetics - Animal \*03506  
Biochemical Studies - General \*10060  
Nervous System - General; Methods \*20501  
Biophysics - General Biophysical Studies \*10502  
**General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals \*00520**  
BC Muridae 86375  
IT Major Concepts  
Molecular Genetics (Biochemistry and Molecular Biophysics); Nervous System (Neural Coordination); Tumor Biology  
IT Diseases  
brain tumor: neoplastic disease, nervous system disease, progression  
IT Chemicals & Biochemicals  
p53 tumor suppressor protein: chromosomal instability, inactivation  
IT Alternate Indexing  
Brain Neoplasms (MeSH)  
IT Methods & Equipment  
**comparative genomic hybridization:**  
genetic method; in-situ **hybridization:** genetic method  
IT Miscellaneous Descriptors  
**Meeting Abstract**  
ORGN Super Taxa  
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia  
ORGN Organism Name  
mouse (Muridae)  
ORGN Organism Superterms  
Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Rodents; Vertebrates

L98 ANSWER 10 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 2000:216415 BIOSIS  
DN PREV200000216415  
TI Genomic copy number changes measured by CGH and quantitative PCR are correlated with clinical outcome in ovarian cancer patients.  
AU Suzuki, Seiji (1); Ginzinger, David; Godfrey, Tony; Moore, Dan; Barclay, John; Powell, Bethan; Pinkel, Dan; Zaloudek, Charles; Berchuck, Andrew; Gray, Joe  
CS (1) Duke Univ, Raleigh-Durham, NC USA  
SO **Proceedings of the American Association for Cancer Research Annual Meeting**, (March, 2000) No. 41, pp. 419.  
Meeting Info.: **91st Annual Meeting of the American Association for Cancer Research**. San Francisco, California, USA April 01-05, 2000  
ISSN: 0197-016X.  
DT **Conference**  
LA English

SL English  
 CC Genetics and Cytogenetics - Human \*03508  
 Biochemical Studies - General \*10060  
 Reproductive System - General; Methods \*16501  
 Neoplasms and Neoplastic Agents - General \*24002  
**General Biology - Symposia, Transactions and Proceedings of  
 Conferences, Congresses, Review Annuals \*00520**  
 BC Hominidae 86215  
 IT Major Concepts  
 Molecular Genetics (Biochemistry and Molecular Biophysics);  
 Reproductive System (Reproduction); Tumor Biology  
 IT Diseases  
 ovarian cancer: neoplastic disease, reproductive system disease/female  
 IT Chemicals & Biochemicals  
 chromosome 1; chromosome 13; chromosome 16; chromosome 17; chromosome  
 18; chromosome 20; chromosome 3; chromosome 4; chromosome 7; chromosome  
 8; chromosome X  
 IT Alternate Indexing  
 Ovarian Neoplasms (MeSH)  
 IT Methods & Equipment  
 PCR [polymerase chain reaction]: DNA amplification, analytical method,  
 in-situ recombinant gene expression detection, sequencing techniques;  
**comparative genomic hybridization:**  
 analytical method  
 IT Miscellaneous Descriptors  
 chromosomal alterations; disease survival; genomic copy number;  
 outcome; tumor grade; tumor stage; **Meeting Abstract**  
 ORGN Super Taxa  
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia  
 ORGN Organism Name  
 human (Hominidae): female, patient  
 ORGN Organism Superterms  
 Animals; Chordates; Humans; Mammals; Primates; Vertebrates

L98 ANSWER 11 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
 AN 2000:216412 BIOSIS  
 DN PREV200000216412  
 TI Comparison of p53 mutations and genome copy number abnormalities measured  
 using CGH in human breast cancers.  
 AU Chin, K. (1); Moore, D.; Erikstein, B.; Karresen, R.; Lonning, P. E.;  
 Boerresen-Dale, A.-L.; Gray, J. W.  
 CS (1) Haukeland Hospital, Oslo Norway  
 SO **Proceedings of the American Association for Cancer Research Annual  
 Meeting, (March, 2000) No. 41, pp. 418.**  
 Meeting Info.: **91st Annual Meeting of the American Association for  
 Cancer Research.** San Francisco, California, USA April 01-05, 2000  
 ISSN: 0197-016X.

DT **Conference**  
 LA English  
 SL English  
 CC Genetics and Cytogenetics - Human \*03508  
 Biochemical Studies - General \*10060  
 Reproductive System - General; Methods \*16501  
 Neoplasms and Neoplastic Agents - General \*24002  
**General Biology - Symposia, Transactions and Proceedings of  
 Conferences, Congresses, Review Annuals \*00520**  
 BC Hominidae 86215  
 IT Major Concepts  
 Molecular Genetics (Biochemistry and Molecular Biophysics); Respiratory  
 System (Respiration); Tumor Biology  
 IT Diseases  
 breast cancer: neoplastic disease, reproductive system disease/female  
 IT Chemicals & Biochemicals

chromosome 12; chromosome 13; chromosome 16; chromosome 17; chromosome 18; chromosome 20; chromosome 3; chromosome 5; chromosome 8; chromosome X; p53

IT Alternate Indexing  
Breast Neoplasms (MeSH)

IT Methods & Equipment  
**comparative genomic hybridization:**  
analytical method; **genome-wide survival association analysis:**  
analytical method

IT Miscellaneous Descriptors  
disease survival; gene mutations; genome copy number; tumor stage;  
**Meeting Abstract**

ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name  
human (Hominidae): patient

ORGN Organism Superterms  
Animals; Chordates; Humans; Mammals; Primates; Vertebrates

L98 ANSWER 12 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 2000:216406 BIOSIS  
DN PREV200000216406  
TI Measurement of DNA sequence copy number alterations by array CGH in human and mouse genomes.

AU Albertson, Donna G. (1); Segraves, Richard (1); Huey, Bing (1); Zhang, Xiao Xiao (1); Palmer, Joel (1); Blackwood, Stephanie (1); Snijders, Antoine (1); Hamilton, Gregory (1); Hindle, Anna Katharine (1); Livezey, Kristin (1); **Gray, Joe W. (1)**; Pinkel, Daniel (1)

CS (1) Univ of CA, San Francisco, San Francisco, CA USA

SO **Proceedings of the American Association for Cancer Research Annual Meeting**, (March, 2000) No. 41, pp. 417.  
Meeting Info.: **91st Annual Meeting of the American Association for Cancer Research**. San Francisco, California, USA April 01-05, 2000  
ISSN: 0197-016X.

DT **Conference**

LA English

SL English

CC Genetics and Cytogenetics - Human \*03508  
Genetics and Cytogenetics - Animal \*03506  
Biochemical Studies - General \*10060  
Neoplasms and Neoplastic Agents - General \*24002  
**General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals \*00520**

BC Hominidae 86215  
Muridae 86375

IT Major Concepts  
Molecular Genetics (Biochemistry and Molecular Biophysics); Tumor Biology

IT Chemicals & Biochemicals  
BAC clones; candidate driver oncogenes; disease genes

IT Methods & Equipment  
PCR [polymerase chain reaction]: DNA amplification, amplification method, in-situ recombinant gene expression detection, sequencing techniques; **comparative genomic hybridization:** analytical method

IT Miscellaneous Descriptors  
DNA sequence copy number; **Meeting Abstract**

ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia; Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name  
human (Hominidae); mouse (Muridae)

ORGN Organism Superterms

Animals; Chordates; Humans; Mammals; Nonhuman Mammals; Nonhuman  
Vertebrates; Primates; Rodents; Vertebrates

- L98 ANSWER 13 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 2000:133691 BIOSIS  
DN PREV200000133691  
TI Oligonucleotide-array-based **comparative genomic hybridization**.  
AU Baldocchi, R. A. (1); Glynne, R. J.; Kowbel, D.; Tom, E.; Collins, C.; Mack, D. H.; Gray, J. W.  
CS (1) University of California at San Francisco Cancer Center, San Francisco, CA, 94143-0808 USA  
SO Breast Cancer Research and Treatment., (1999) Vol. 57, No. 1, pp. 33.  
Meeting Info.: **22nd Annual San Antonio Breast Cancer Symposium**  
San Antonio, Texas, USA December 8-11, 1999  
ISSN: 0167-6806.  
DT **Conference**  
LA English  
SL English  
CC Genetics and Cytogenetics - Human \*03508  
Reproductive System - Pathology \*16506  
Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic Effects \*24004  
**General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals \*00520**  
BC Hominidae 86215  
IT Major Concepts  
Molecular Genetics (Biochemistry and Molecular Biophysics); Tumor Biology  
IT Diseases  
breast cancer: neoplastic disease, reproductive system disease/female, tumor development  
IT Chemicals & Biochemicals  
AIBC-1 gene (Hominidae): tumor development role; BRCA-2 gene (Hominidae): tumor development role; CCND-1 gene (Hominidae): tumor development role; ErbB-2 gene (Hominidae): tumor development role; MYC oncogene (Hominidae): tumor development role; ZNF-217 gene (Hominidae): tumor development role; p53 gene (Hominidae): tumor development role  
IT Alternate Indexing  
Breast Neoplasms (MeSH)  
IT Methods & Equipment  
oligonucleotide array-based **comparative genomic hybridization**: genetic method  
IT Miscellaneous Descriptors  
**Meeting Abstract**  
ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia  
ORGN Organism Name  
human (Hominidae): female, patient  
ORGN Organism Superterms  
Animals; Chordates; Humans; Mammals; Primates; Vertebrates
- L98 ANSWER 14 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 1999:506809 BIOSIS  
DN PREV199900506809  
TI High throughput mapping of Cri du Chat deletions on 5p using **comparative genomic hybridization** to DNA microarrays.  
AU Zhang, X. (1); Segreaves, R. (1); Bolund, L.; Yang, H. M.; Niebuhr, E.; Gray, J. (1); Albertson, D. (1); Pinkel, D. (1)  
CS (1) Cancer Center, UCSF, San Francisco, CA USA  
SO American Journal of Human Genetics, (Oct., 1999) Vol. 65, No. 4, pp. A364.

Meeting Info.: **49th Annual Meeting of the American Society of Human Genetics** San Francisco, California, USA October 19-23, 1999 The American Society of Human Genetics  
. ISSN: 0002-9297.

DT **Conference**  
LA English  
CC Genetics and Cytogenetics - Human \*03508  
Biochemical Studies - General \*10060  
**General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals \*00520**  
BC Hominidae 86215  
IT Major Concepts  
Medical Genetics (Allied Medical Sciences)  
IT Chemicals & Biochemicals  
DNA: microarray; 5p: Cri du Chat deletion  
IT Methods & Equipment  
**comparative genomic hybridization:**  
mapping method; high throughput mapping: mapping method  
IT Miscellaneous Descriptors  
constitutional aberration; diagnostic capability; **Meeting Abstract; Meeting Poster**  
ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia  
ORGN Organism Name  
human (Hominidae)  
ORGN Organism Superterms  
Animals; Chordates; Humans; Mammals; Primates; Vertebrates

L98 ANSWER 15 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 1998:196225 BIOSIS  
DN PREV199800196225  
TI Analysis of DNA sequence copy number variation in breast cancer using **comparative genomic hybridization** to DNA microarrays.  
AU Albertson, D. G. (1); Segraves, R.; Sudar, D. (1); Clark, S.; Collins, C. (1); Chen, C.; Kuo, W.-L.; Kowbel, D. (1); Dairkee, S. H.; Poole, I.; Gray, J. W. (1); Pinkel, D. (1)  
CS (1) E.O. Lawrence Berkeley National Lab., Berkeley, CA USA  
SO **Proceedings of the American Association for Cancer Research Annual Meeting**, (March, 1998) Vol. 39, pp. 345.  
Meeting Info.: **89th Annual Meeting of the American Association for Cancer Research** New Orleans, Louisiana, USA March 28-April 1, 1998 American Association for Cancer Research  
. ISSN: 0197-016X.

DT **Conference**  
LA English  
CC Genetics and Cytogenetics - Human \*03508  
Reproductive System - General; Methods \*16501  
Neoplasms and Neoplastic Agents - General \*24002  
**General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals \*00520**  
BC Hominidae 86215  
IT Major Concepts  
Genetics; Tumor Biology  
IT Diseases  
breast cancer: neoplastic disease, reproductive system disease/female  
IT Chemicals & Biochemicals  
DNA  
IT Methods & Equipment  
**comparative genomic hybridization:**  
analytical method, genetic method  
IT Miscellaneous Descriptors  
sequence copy number variation; **Meeting Abstract**

ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia  
ORGN Organism Name  
human (Hominidae)  
ORGN Organism Superterms  
Animals; Chordates; Humans; Mammals; Primates; Vertebrates

L98 ANSWER 16 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 1998:190153 BIOSIS  
DN PREV199800190153  
TI High resolution analysis of DNA copy number variation using  
**comparative genomic hybridization** to DNA  
microarrays.  
AU Pinkel, D. (1); Segraves, R.; Sudar, D.; Poole, S. Clark I.; Jones, A.;  
**Collins, C.**; Zou, Y.; Dairkee, S.; **Gray, J.**; Albertson,  
D. (1)  
CS (1) Univ. Calif. San Francisco, San Francisco, CA USA  
SO Cytometry, (1998) No. SUPPL. 9, pp. 24-25.  
Meeting Info.: **XIX International Congress of the International  
Society for Analytical Cytology** Colorado Springs, Colorado, USA  
February 28-March 5, 1998 International Society for Analytical Cytology  
. ISSN: 0196-4763.  
DT **Conference**  
LA English  
CC Microscopy Techniques - General and Special Techniques \*01052  
Cytology and Cytochemistry - General \*02502  
Genetics and Cytogenetics - General \*03502  
Biochemical Studies - General \*10060  
Biophysics - General Biophysical Studies \*10502  
**General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals \*00520**  
IT Major Concepts  
Methods and Techniques; Molecular Genetics (Biochemistry and Molecular  
Biophysics)  
IT Chemicals & Biochemicals  
DNA: copy number variation, high resolution analysis, microarray  
IT Methods & Equipment  
**comparative genomic hybridization:**  
detection method  
IT Miscellaneous Descriptors  
**Meeting Abstract**

L98 ANSWER 17 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 1998:190136 BIOSIS  
DN PREV199800190136  
TI Genomics, molecular cytogenetics and cytometry.  
AU **Gray, Joe W. (1)**  
CS (1) UCSF Cancer Cent., Univ. Calif., San Francisco, CA USA  
SO Cytometry, (1998) No. SUPPL. 9, pp. 20.  
Meeting Info.: **XIX International Congress of the International  
Society for Analytical Cytology** Colorado Springs, Colorado, USA  
February 28-March 5, 1998 International Society for Analytical Cytology  
. ISSN: 0196-4763.  
DT **Conference**  
LA English  
CC Cytology and Cytochemistry - General \*02502  
Microscopy Techniques - General and Special Techniques \*01052  
Genetics and Cytogenetics - General \*03502  
Biophysics - General Biophysical Studies \*10502  
**General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals \*00520**  
IT Major Concepts  
Cell Biology; Methods and Techniques; Molecular Genetics (Biochemistry

- and Molecular Biophysics)
- IT Methods & Equipment  
**comparative genomic hybridization:**  
 analytical method; cytometry: analytical method, cytological method;  
 fluorescence in situ **hybridization** [FISH]: analytical method;  
 quantitative PCR [quantitative polymerase chain reaction]: analytical  
 method
- IT Miscellaneous Descriptors  
 genomics; molecular cytogenetics; **Meeting Abstract**
- L98 ANSWER 18 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
 AN 1996:397422 BIOSIS  
 DN PREV199699119778  
 TI Genetic progression in breast cancer; chaos and consistency.  
 AU **Gray, J. W. (1)**; Hwang, S.; Godfrey, T. (1); Kowbel, D.;  
 Kallioniemi, O.; Tanner, M.; Isola, J.; Pinkel, F. D. (1); Waldman, F.  
 (1); Rommens, J.; **Collins, C.**  
 CS (1) Univ. California, San Francisco, CA USA  
 SO Journal of Histochemistry and Cytochemistry, (1996) Vol. 44, No. 7, pp.  
 783.  
 Meeting Info.: **47th Annual Meeting of the Histochemical Society**  
 Bethesda, Maryland, USA August 2-3, 1996  
 ISSN: 0022-1554.
- DT **Conference**  
 LA English
- CC **General Biology - Symposia, Transactions and Proceedings of**  
**Conferences, Congresses, Review Annuals 00520**  
 Microscopy Techniques - Cytology and Cytochemistry \*01054  
 Cytology and Cytochemistry - Human \*02508  
 Genetics and Cytogenetics - General \*03502  
 Genetics and Cytogenetics - Human \*03508  
 Reproductive System - Pathology \*16506  
 Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic  
 Effects \*24004
- BC Hominidae \*86215
- IT Major Concepts  
 Cell Biology; Genetics; Methods and Techniques; Oncology (Human  
 Medicine, Medical Sciences); Reproductive System (Reproduction)
- IT Miscellaneous Descriptors  
 ANALYTICAL METHOD; CHROMOSOMAL ABERRATION; **COMPARATIVE**  
**GENOMIC HYBRIDIZATION**; DIAGNOSIS; FLUORESCENCE  
 IN-SITU **HYBRIDIZATION**; **MEETING ABSTRACT**;  
 PROGNOSIS; THERAPY DEVELOPMENT
- ORGN Super Taxa  
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
- ORGN Organism Name  
 human (Hominidae)
- ORGN Organism Superterms  
 animals; chordates; humans; mammals; primates; vertebrates
- L98 ANSWER 19 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
 AN 1995:476679 BIOSIS  
 DN PREV199598490979  
 TI Genetic analyses of borderline ovarian tumor using **comparative**  
**genomic hybridization.**
- AU Iwabuchi, Hiroshi (1); Sakunaga, Hotaka; Sakamoto, Masaru; Yang-Feng,  
 Teresa L.; Pinkel, Dan (1); **Gray, Joe W. (1)**
- CS (1) Dep. Lab. Med., Univ. Calif., San Francisco, CA USA
- SO American Journal of Human Genetics, (1995) Vol. 57, No. 4 SUPPL., pp. A67.  
 Meeting Info.: **45th Annual Meeting of the American Society of Human**  
**Genetics** Minneapolis, Minnesota, USA October 24-28, 1995  
 ISSN: 0002-9297.
- DT **Conference**

LA English  
CC **General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals 00520**  
Cytology and Cytochemistry - Human \*02508  
Genetics and Cytogenetics - Human \*03508  
Reproductive System - Pathology \*16506  
Neoplasms and Neoplastic Agents - General \*24002  
Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic  
Effects \*24004  
Neoplasms and Neoplastic Agents - Carcinogens and Carcinogenesis \*24007  
BC Hominidae \*86215  
IT Major Concepts  
Cell Biology; Genetics; Oncology (Human Medicine, Medical Sciences);  
Reproductive System (Reproduction)  
IT Miscellaneous Descriptors  
CHROMOSOME; COPY NUMBER ABNORMALITY; **MEETING ABSTRACT**  
; **MEETING POSTER**  
ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia  
ORGN Organism Name  
human (Hominidae)  
ORGN Organism Superterms  
animals; chordates; humans; mammals; primates; vertebrates

L98 ANSWER 20 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 1995:185532 BIOSIS  
DN PREV199598199832  
TI Genetic progression model in ovarian cancer with **comparative  
genomic hybridization** (CGH).  
AU Iwabuchi, H. (1); Sakunaga, H.; Sakamoto, M.; Yang-Feng, T. L.; Pinkel,  
D.; Gray, J. W.  
CS (1) Dep. Lab. Med., Univ. Calif., San Francisco, CA USA  
SO **Proceedings of the American Association for Cancer Research Annual  
Meeting**, (1995) Vol. 36, No. 0, pp. 226.  
Meeting Info.: **Eighty-sixth Annual Meeting of the American  
Association for Cancer Research** Toronto, Ontario, Canada March 18-22,  
1995  
ISSN: 0197-016X.  
DT **Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals 00520**  
Genetics and Cytogenetics - Human \*03508  
Reproductive System - Pathology \*16506  
Neoplasms and Neoplastic Agents - Carcinogens and Carcinogenesis \*24007  
BC Hominidae \*86215  
IT Major Concepts  
Genetics; Oncology (Human Medicine, Medical Sciences); Reproductive  
System (Reproduction)  
IT Miscellaneous Descriptors  
CHROMOSOMAL ABERRATION; **MEETING ABSTRACT**  
ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia  
ORGN Organism Name  
human (Hominidae)  
ORGN Organism Superterms  
animals; chordates; humans; mammals; primates; vertebrates

L98 ANSWER 21 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 1995:185307 BIOSIS  
DN PREV199598199607  
TI CGH analysis of mammary tumors from Wnt-1 transgenic mice demonstrates a  
dependence of chromosome stability on p53 status.



AU Shi, Y.-P. (1); Godley, L. A.; Donehower, L. A.; Varmus, H. E.; **Gray, J. W. (1)**; Pinkel, D. (1)  
CS (1) Dep. Lab. Med., Univ. California, San Francisco, CA 94143 USA  
SO **Proceedings of the American Association for Cancer Research Annual Meeting**, (1995) Vol. 36, No. 0, pp. 188.  
Meeting Info.: **Eighty-sixth Annual Meeting of the American Association for Cancer Research** Toronto, Ontario, Canada March 18-22, 1995  
ISSN: 0197-016X.  
DT **Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**  
Cytology and Cytochemistry - Animal \*02506  
Genetics and Cytogenetics - Animal \*03506  
Biophysics - General Biophysical Techniques 10504  
Biophysics - Molecular Properties and Macromolecules 10506  
Reproductive System - Pathology \*16506  
Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic Effects \*24004  
Neoplasms and Neoplastic Agents - Carcinogens and Carcinogenesis \*24007  
BC Muridae \*86375  
IT Major Concepts  
Cell Biology; Genetics; Reproductive System (Reproduction); Tumor Biology  
IT Miscellaneous Descriptors  
ANALYTICAL METHOD; CARCINOGENESIS; **COMPARATIVE GENOMIC HYBRIDIZATION; MEETING ABSTRACT**  
ORGN Super Taxa  
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia  
ORGN Organism Name  
Muridae (Muridae)  
ORGN Organism Superterms  
animals; chordates; mammals; nonhuman vertebrates; nonhuman mammals; rodents; vertebrates  
  
L98 ANSWER 22 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 1994:526383 BIOSIS  
DN PREV199497539383  
TI Resource for molecular cytogenetic analysis.  
AU Kuo, W.-L. (1); **Collins, C.**; Weier, U.; Sudar, D.; Mullikin, J.; Lockett, S.; Riedell, L. (1); Yue, P. (1); Kowbel, D.; Shadravan, F.; Pinkel, D. (1); **Gray, J. (1)**  
CS (1) LBL/USCF Resource Mol. Cytogenetics, Dep. Lab. Med., Univ. Calif., San Francisco, CA USA  
SO American Journal of Human Genetics, (1994) Vol. 55, No. 3 SUPPL., pp. A372.  
Meeting Info.: **44th Annual Meeting of the American Society of Human Genetics** Montreal, Quebec, Canada October 18-22, 1994  
ISSN: 0002-9297.  
DT **Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520**  
Cytology and Cytochemistry - Human \*02508  
Genetics and Cytogenetics - Human \*03508  
Biophysics - Molecular Properties and Macromolecules \*10506  
BC Hominidae \*86215  
IT Major Concepts  
Cell Biology; Genetics  
IT Miscellaneous Descriptors  
**COMPARATIVE GENOMIC ANALYSIS; FLUORESCENCE IN SITU**

**HYBRIDIZATION; MEETING ABSTRACT; MOLECULAR  
GENETICS; PHYSICAL MAP**

ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name  
human (Hominidae)

ORGN Organism Superterms  
animals; chordates; humans; mammals; primates; vertebrates

L98 ANSWER 23 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 1994:524526 BIOSIS  
DN PREV199497537526  
TI Model of genetic progression in ovarian cancer with **comparative  
genomic hybridization.**  
AU Iwabuchi, H. (1); Sakamoto, M. (1); Sakunaga, H. (1); Yang-Feng, T. L.;  
**Gray, J. W. (1)**  
CS (1) Dep. Lab. Med., Univ. Calif. San Francisco, CA USA  
SO American Journal of Human Genetics, (1994) Vol. 55, No. 3 SUPPL., pp. A60.  
Meeting Info.: **44th Annual Meeting of the American Society of Human  
Genetics** Montreal, Quebec, Canada October 18-22, 1994  
ISSN: 0002-9297.

DT **Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals 00520**  
Cytology and Cytochemistry - Human \*02508  
Genetics and Cytogenetics - Human \*03508  
Reproductive System - Pathology \*16506  
Neoplasms and Neoplastic Agents - Carcinogens and Carcinogenesis \*24007

BC Hominidae \*86215  
IT Major Concepts  
Cell Biology; Genetics; Oncology (Human Medicine, Medical Sciences);  
Reproductive System (Reproduction)

IT Miscellaneous Descriptors  
**CHROMOSOMAL ABERRATION; MEETING ABSTRACT;  
MEETING POSTER; TUMOR PROGRESSION**

ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name  
human (Hominidae)

ORGN Organism Superterms  
animals; chordates; humans; mammals; primates; vertebrates

L98 ANSWER 24 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 1994:289270 BIOSIS  
DN PREV199497302270  
TI Genetic events underlying breast cancer progression analyzed by  
**comparative genomic hybridization.**  
AU Kallioniemi, O.-P. (1); Isola, J.; Kallioniemi, A.; Tanner, M.; Stokke,  
T.; Heintz, M.; **Collins, C.**; Smith, H. S.; Fuqua, S.; Pinkel,  
D.; **Gray, J. W.**; Waldman, F.  
CS (1) Univ. Tampere, 33521 Tampere Finland  
SO **Proceedings of the American Association for Cancer Research Annual  
Meeting**, (1994) Vol. 35, No. 0, pp. 250.  
Meeting Info.: **85th Annual Meeting of the American Association for  
Cancer Research** San Francisco, California, USA April 10-13, 1994  
ISSN: 0197-016X.

DT **Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals 00520**  
Cytology and Cytochemistry - Human 02508  
Genetics and Cytogenetics - Human \*03508

Reproductive System - Pathology \*16506  
Neoplasms and Neoplastic Agents - Carcinogens and Carcinogenesis \*24007  
BC Hominidae \*86215  
IT Major Concepts  
    Genetics; Oncology (Human Medicine, Medical Sciences); Reproductive  
    System (Reproduction)  
IT Miscellaneous Descriptors  
    CARCINOGENESIS; **MEETING ABSTRACT**  
ORGN Super Taxa  
    Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia  
ORGN Organism Name  
    human (Hominidae)  
ORGN Organism Superterms  
    animals; chordates; humans; mammals; primates; vertebrates

L98 ANSWER 25 OF 25 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.  
AN 1993:378583 BIOSIS  
DN PREV199345050008  
TI Analysis of genetic aberrations in ovarian cancers using  
    **comparative genomic hybridization.**  
AU Sakamoto, M. (1); Sakunaga, H. (1); Yang-Feng, T.; Li, S.; Kallioniemi, A.  
    (1); Kallioniemi, O. (1); Pinkel, D. (1); **Gray, J. (1)**  
CS (1) Univ. Calif., San Francisco, CA USA  
SO **Proceedings of the American Association for Cancer Research Annual  
Meeting, (1993) Vol. 34, No. 0, pp. 210.**  
    Meeting Info.: **84th Annual Meeting of the American Association for  
Cancer Research** Orlando, Florida, USA May 19-22, 1993  
    ISSN: 0197-016X.  
DT **Conference**  
LA English  
CC **General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals 00520**  
    Cytology and Cytochemistry - Human \*02508  
    Genetics and Cytogenetics - Human \*03508  
    Biochemical Studies - General 10060  
    Pathology, General and Miscellaneous - Diagnostic \*12504  
    Reproductive System - Pathology \*16506  
    Neoplasms and Neoplastic Agents - Diagnostic Methods \*24001  
BC Hominidae \*86215  
IT Major Concepts  
    Cell Biology; Genetics; Oncology (Human Medicine, Medical Sciences);  
    Pathology; Reproductive System (Reproduction)  
IT Miscellaneous Descriptors  
    **ABSTRACT; CHROMOSOME 19; DIAGNOSTIC METHOD; GENE COPY NUMBER**  
ORGN Super Taxa  
    Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia  
ORGN Organism Name  
    human (Hominidae)  
ORGN Organism Superterms  
    animals; chordates; humans; mammals; primates; vertebrates

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 17:02:04 ON 15 JUL 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

L66 ANSWER 2 OF 3 MEDLINE  
AN 94063908 MEDLINE  
DN 94063908 PubMed ID: 8244381  
TI Ordered shotgun sequencing, a strategy for integrated mapping and sequencing of YAC clones.  
AU Chen E Y; Schlessinger D; Kere J  
CS Advanced Center for Genetic Technology, Applied Biosystems, Inc., Foster City, California 94404.  
NC HG00247 (NHGRI)  
SO GENOMICS, (1993 Sep) 17 (3) 651-6.  
Journal code: 8800135. ISSN: 0888-7543.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199312  
ED Entered STN: 19940201  
Last Updated on STN: 19980206  
Entered Medline: 19931229  
AB Ordered shotgun sequencing proposes to organize the mapping and sequencing of YACs with a hierarchical strategy that incorporates a feedback loop. Building on current protocols, a YAC is subcloned into plasmids, plasmid insert ends are sequenced, and the sequences are overlapped to create a partial map. Complete sequencing then starts with plasmids whose **end-sequence** tracts have overlapped, but to a minimal extent. The next plasmids to be sequenced are again selected for least overlap, striking out progressively to span the YAC with minimal directed gap-filling. Simulations support its feasibility and indicate that during the generation of the complete sequence, the approach facilitates the early choice of regions for selective sequencing, for example, for coding units. The sequencing of plasmids would also require less redundancy, and discriminate repetitive sequences more easily, than random sequencing across larger clones. The overall effort scales with YAC size and can be further reduced by additional mapping information.  
CT Check Tags: Human; Support, U.S. Gov't, P.H.S.  
\*Chromosome Mapping: MT, methods  
\*Chromosomes, Artificial, Yeast  
Cloning, Molecular  
Computer Simulation  
Evaluation Studies  
Genome, Human  
Models, Genetic  
Plasmids: GE, genetics  
\*Sequence Analysis, DNA: MT, methods  
Sequence Tagged Sites  
CN 0 (Chromosomes, Artificial, Yeast); 0 (Plasmids)

L66 ANSWER 3 OF 3 MEDLINE  
AN 90272391 MEDLINE  
DN 90272391 PubMed ID: 2161516  
TI A novel, rapid method for the isolation of **terminal sequences** from yeast artificial chromosome (YAC) clones.  
AU Riley J; Butler R; Ogilvie D; Finnear R; Jenner D; Powell S; Anand R; Smith J C; Markham A F  
CS ICI Pharmaceuticals, Biotechnology Department, Macclesfield, Cheshire, UK.  
SO NUCLEIC ACIDS RESEARCH, (1990 May 25) 18 (10) 2887-90.  
Journal code: 0411011. ISSN: 0305-1048.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
OS GENBANK-X52166; GENBANK-X52167  
EM 199007

ED Entered STN: 19900810  
Last Updated on STN: 19900810  
Entered Medline: 19900711

AB The recent development of yeast artificial chromosome (YAC) vectors has provided a system for cloning fragments that are over ten times larger than those that can be cloned in more established systems. We have developed a method for the rapid isolation of **terminal sequences** from YAC clones. The YAC clone is digested with a range of restriction enzymes, a common linker is ligated to the DNA fragments and **terminal sequences** are amplified using a vector specific primer and a linker specific primer. Sequence data derived from these terminal specific products can be used to design primers for a further round of screening to isolate overlapping clones. The method also provides a convenient method of generating Sequence Tagged Sites for the mapping of complex genomes.

CT **Base Sequence**  
Chromosomes, Fungal  
Cloning, Molecular  
DNA Restriction Enzymes  
Gene Amplification  
\*Gene Library  
\*Genetic Techniques  
Genetic Vectors  
Molecular Sequence Data  
Restriction Mapping  
Saccharomyces cerevisiae: GE, genetics

CN 0 (Genetic Vectors); EC 3.1.21 (DNA Restriction Enzymes)

=> d his

(FILE 'HOME' ENTERED AT 13:38:54 ON 16 JUL 2003)  
SET COST OFF

FILE 'WPIX' ENTERED AT 13:39:03 ON 16 JUL 2003

E WO2001075856/PN  
L1 1 S E3  
E WO2001092558/PN  
L2 1 S E3  
E COLLINS C/AU  
L3 129 S E3-E20  
E GRAY J/AU  
L4 130 S E3,E21  
E VOLIK S/AU  
L5 3 S E3,E4  
L6 27092 S (B04-E01 OR C04-E01 OR B04-B04A1 OR C04-B04A1)/MC  
L7 13925 S (B04-E05 OR C04-E05)/MC  
L8 1664 S (B11-C08F OR C11-C08F OR B11-C08F1 OR C11-C08F1 OR B11-C08G O  
L9 16893 S (B12-K04F OR C12-K04F)/MC  
L10 15771 S D05-H12/MC  
L11 864 S D05-H12D/MC  
L12 13766 S D05-H12D1/MC  
L13 14157 S D05-H18?/MC  
L14 46 S L3-L5 AND L6-L12  
L15 52 S C12Q/IC, ICM, ICS AND L3-L5  
L16 55 S L14,L15  
L17 194 S L3-L5 NOT L16  
L18 55 S L1,L2,L16  
L19 2 S L18 AND G06F/IC, ICM, ICS, ICA, ICI  
L20 3 S L18 AND T?/MC  
L21 5 S L19,L20  
L22 4 S L21 NOT PRINT HEAD/TI  
L23 50 S L18 NOT L19-L22  
SEL DN AN 8 10 20 40  
L24 4 S E1-E8  
L25 8 S L22,L24 AND L1-L14

FILE 'WPIX' ENTERED AT 14:08:52 ON 16 JUL 2003

FILE 'DPCI' ENTERED AT 14:09:55 ON 16 JUL 2003  
E WO2001092558/PN

L26 1 S E3

FILE 'DPCI' ENTERED AT 14:10:25 ON 16 JUL 2003

FILE 'WPIX' ENTERED AT 14:11:07 ON 16 JUL 2003

L27 2 S (US5830645 OR US6013439)/PN  
L28 1 S L27 NOT L25

FILE 'WPIX' ENTERED AT 14:11:35 ON 16 JUL 2003

FILE 'MEDLINE' ENTERED AT 14:12:05 ON 16 JUL 2003

L29 1 S ALTSCHUL ?/AU AND 1990/PY AND (215 AND 403)/SO

FILE 'MEDLINE' ENTERED AT 14:12:55 ON 16 JUL 2003

E CHROMOSOMES/CT  
E E3+ALL  
L30 143086 S E17+NT  
E CHROMOSOM/CT  
E E6+ALL  
E E2+ALL  
L31 88566 S E8+NT  
L32 189199 S L30,L31  
E MOLECULAR SEQUENCE/CT

```

      E E4+ALL
L33    374736 S E5
L34    335581 S E30+NT
      E E76+ALL
L35    34652 S E4
L36    38406 S L32 AND L33-L35
      E SEQUENCE ANALYSIS/CT
      E E3+ALL
L37    68649 S E4+NT
L38    3995 S L36 AND L37
L39    355 S L32 AND (END OR TERMINAL)()SEQUENC?
L40    8126 S L33-L35 AND (END OR TERMINAL)()SEQUENC?
L41    1352 S L37 AND (END OR TERMINAL)()SEQUENC?
L42    7622 S L39-L41 AND PY<=2000
L43    297 S L42 AND L32
      E CONTIG MAPPING/CT
      E E3+ALL
      E E8+ALL
      E E4+ALL
L44    93240 S E4+NT
L45    690 S L44 AND L42
L46    146 S L43 AND L45
L47    7322 S L42 AND L1./CT
L48    225 S L47 AND L43
L49    113 S L47 AND L46
      E CLONING/CT
      E E9+ALL
L50    117415 S E4+NT
L51    102339 S L50 AND PY<=2000
L52    1934 S L51 AND (END OR TERMINAL)()SEQUENC?
L53    130 S L52 AND L32
      E GENOME/CT
      E E3 ALL
      E GENOME/CT
      E E3+ALL
L54    43036 S E6+NT
      E E5+ALL
L55    129 S L52 AND L54
L56    378 S L52 AND E4+NT
L57    428 S L55,L56
L58    72 S L49 AND L50
L59    366 S END SEQUENC? AND PY<=2000
L60    10683 S TERMINAL SEQUENC? AND PY<=2000
L61    81 S L59 AND L32
L62    217 S L60 AND L32
      SEL DN AN L61 32 66
L63    2 S L61 AND E1-E6
L64    216 S L62 NOT L61
      SEL DN AN 140 L64
L65    1 S L64 AND E7-E9
L66    3 S L63,L65 AND L30-L65

```

FILE 'MEDLINE' ENTERED AT 14:40:14 ON 16 JUL 2003